<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
<journal-title-group>
<journal-title>Orphanet Journal of Rare Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1750-1172</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31964424</article-id>
<article-id pub-id-type="pmc">6975094</article-id>
<article-id pub-id-type="publisher-id">1258</article-id>
<article-id pub-id-type="doi">10.1186/s13023-019-1258-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zöllner</surname>
<given-names>Johann Philipp</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franz</surname>
<given-names>David Neal</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hertzberg</surname>
<given-names>Christoph</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nabbout</surname>
<given-names>Rima</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenow</surname>
<given-names>Felix</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sauter</surname>
<given-names>Matthias</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schubert-Bast</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wiemer-Kruel</surname>
<given-names>Adelheid</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6288-9915</contrib-id>
<name>
<surname>Strzelczyk</surname>
<given-names>Adam</given-names>
</name>
<address>
<email>strzelczyk@med.uni-frankfurt.de</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution>Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, </institution><institution>Goethe-University Frankfurt, </institution></institution-wrap>Frankfurt am Main, Germany </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution>LOEWE Center for Personalized Translational Epilepsy Research (CePTER), </institution><institution>Goethe-University Frankfurt, </institution></institution-wrap>Frankfurt am Main, Germany </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 9593</institution-id><institution-id institution-id-type="GRID">grid.24827.3b</institution-id><institution>Children’s Hospital Medical Center, </institution><institution>University of Cincinnati College of Medicine, </institution></institution-wrap>Cincinnati, OH USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0476 8412</institution-id><institution-id institution-id-type="GRID">grid.433867.d</institution-id><institution>Zentrum für Sozialpädiatrie &amp; Neuropädiatrie (DBZ), </institution><institution>Vivantes Klinikum Neukölln, </institution></institution-wrap>Berlin, Germany </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2188 0914</institution-id><institution-id institution-id-type="GRID">grid.10992.33</institution-id><institution>Department of Pediatric Neurology, Necker Enfants Malades Hospital, </institution><institution>Paris Descartes University, Imagine Institute UMR1136, </institution></institution-wrap>Paris, France </aff>
<aff id="Aff6"><label>6</label>Klinikverbund Kempten-Oberallgäu gGmbH, Kempten, Germany </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution>Department of Neuropediatrics, </institution><institution>Goethe-University Frankfurt, </institution></institution-wrap>Frankfurt am Main, Germany </aff>
<aff id="Aff8"><label>8</label>Clinic for Children and Adolescents, Epilepsy Center Kork, Kehl-Kork, Germany </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9756</institution-id><institution-id institution-id-type="GRID">grid.10253.35</institution-id><institution>Epilepsy Center Hessen and Department of Neurology, </institution><institution>Philipps-University Marburg, </institution></institution-wrap>Marburg (Lahn), Germany </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution>Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, </institution><institution>Goethe-University Frankfurt, </institution></institution-wrap>Schleusenweg 2-16 (Haus 95), 60528 Frankfurt am Main, Germany </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>15</volume>
<elocation-id>23</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Objective</title>
<p id="Par1">This review will summarize current knowledge on the burden of illness (BOI) in tuberous sclerosis complex (TSC), a multisystem genetic disorder manifesting with hamartomas throughout the body, including mainly the kidneys, brain, skin, eyes, heart, and lungs.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We performed a systematic analysis of the available literature on BOI in TSC according to the PRISMA guidelines. All studies irrespective of participant age that reported on individual and societal measures of disease burden (e.g. health care resource use, costs, quality of life) were included.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">We identified 33 studies reporting BOI in TSC patients. Most studies (21) reported health care resource use, while 14 studies reported quality of life and 10 studies mentioned costs associated with TSC. Only eight research papers reported caregiver BOI. Substantial BOI occurs from most manifestations of the disorder, particularly from pharmacoresistant epilepsy, neuropsychiatric, renal and skin manifestations. While less frequent, pulmonary complications also lead to a high individual BOI. The range for the mean annual direct costs varied widely between 424 and 98,008 International Dollar purchasing power parities (PPP-$). Brain surgery, end-stage renal disease with dialysis, and pulmonary complications all incur particularly high costs. There is a dearth of information regarding indirect costs in TSC. Mortality overall is increased compared to general population; and most TSC related deaths occur as a result of complications from seizures as well as renal complications. Long term studies report mortality between 4.8 and 8.3% for a follow-up of 8 to 17.4 years.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">TSC patients and their caregivers have a high burden of illness, and TSC patients incur high costs in health care systems. At the same time, the provision of inadequate treatment that does not adhere to published guidelines is common and centralized TSC care is received by no more than half of individuals who need it, especially adults. Further studies focusing on the cost effectiveness and BOI outcomes of coordinated TSC care as well as of new treatment options such as mTOR inhibitors are necessary.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003495</institution-id>
<institution>Hessisches Ministerium für Wissenschaft und Kunst</institution>
</institution-wrap>
</funding-source>
<award-id>LOEWE CePTER</award-id>
<principal-award-recipient>
<name>
<surname>Strzelczyk</surname>
<given-names>Adam</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par5">Tuberous sclerosis complex (TSC) is a rare genetic disorder that affects about 1 in 5000 individuals worldwide [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Its prevalence was until recently underestimated due to incomplete penetrance and the considerable interindividual phenotypic variability in individuals with TSC [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. TSC can affect many organs, leading to benign tumors presenting preferentially in the skin, brain, and kidneys. The clinical manifestation of the disorder changes during life in a typical pattern. Many individuals are first diagnosed by pathognomonic skin manifestations or secondarily after experiencing seizures, as most individuals with TSC are affected by a structural epilepsy due to cortical tubers or other cortical malformations. The clinical picture of TSC is very broad and can range from mild symptoms that do not limit the individual to manifestations with severe disabilities in multiple organ systems, often involving intellectual impairment.</p>
<p id="Par6">TSC is caused by mutations in the <italic>TSC1</italic> or <italic>TSC2</italic> gene. It is inherited in an autosomal-dominant fashion, but most cases are due to apparent de novo mutations. Genetic mosaicism and deep intronic mutations probably contributes to the disorder in the 15% of individuals where no definitive hereditary mutation can be found despite a definite clinical diagnosis of TSC [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
<p id="Par7">Burden of illness (BOI) describes the impact of a health problem on the individual and society as a whole. BOI includes an epidemiological domain which encompasses both the years of life lost due to the disease (mortality) as well as the morbidity, which refers to disease prevalence and associated years with reduced health. The economic domain of the BOI comprises direct and indirect costs as well as health care resource utilization [<xref ref-type="bibr" rid="CR11">11</xref>]. Direct costs reflect costs to the individual or health care system and can be easily quantified (e.g. co-payments, cost of hospital admission) [<xref ref-type="bibr" rid="CR12">12</xref>]. In contrast, indirect costs contain financial and social burden to the individual and his surroundings (e.g. a parent’s time lost from work) and may be less quantifiable [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Health care utilization reflects resources used by the patient or his caregivers in an inpatient or outpatient setting, including medication and other medical treatment (e.g. physiotherapy, logopedic therapy). Individual BOI is usually expressed as quality of life (QoL) and is measured by standardized questionnaires.</p>
<p id="Par8">The burden of illness in TSC is highly variable and determined by the condition’s complex and multifaceted disorder manifestations. These manifestations and their clinical significance vary widely between persons with TSC as well as throughout individual’s lifetime. In addition, the relevance of specific manifestations may be assessed differently between the individual with TSC, his/her caregivers, and the treating health care providers – a general problem when evaluating the BOI in any disease with medical or economic approaches.</p>
<p id="Par9">The first comprehensive review on the burden of illness in TSC was published by Hallett et al. in 2011 [<xref ref-type="bibr" rid="CR15">15</xref>], with the majority of studies on this topic published in the time since then. An outstanding review on genetic, clinical, and therapeutic aspects of TSC was presented by Henske et al. in 2016 [<xref ref-type="bibr" rid="CR16">16</xref>], but BOI was not addressed in this review in detail.</p>
<p id="Par10">Thus, the present article aims to give a systematic review of the known factors that contribute to the BOI in individuals with TSC and their caregivers. The clinical picture of TSC is summarized in order to aid interpretation of the health burden.</p>
</sec>
<sec id="Sec2">
<title>Materials and methods</title>
<p id="Par11">We performed a structured analysis of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [<xref ref-type="bibr" rid="CR17">17</xref>]. We included 33 articles covering both children and adults with TSC which reported data on BOI in TSC in the systematic review, while information from these and further articles was used for a non-systematic clinical summary. Studies included featured noninterventional retrospective, prospective, and cross-sectional as well as interventional designs. We defined the following relevant parameters: incidence and prevalence of organ system manifestations; individual morbidity and mortality (described as disease-adjusted life years (DALY) and quality-adjusted life years (QALY), where available); resource utilization of health care systems (described in total use of health care resources) and direct as well as indirect costs. Caregiver burden was assessed as well. Costs were extracted as given in the source and then converted into 2018 International Dollar purchasing power parities (PPP-$) according to the method described by Strzelczyk et al. [<xref ref-type="bibr" rid="CR18">18</xref>]. In short, inflation data were retrieved for each country from the Organization for Economic Co-Operation and Development (OECD) Stat database [<xref ref-type="bibr" rid="CR19">19</xref>]. PPP were defined as the rates of currency conversion that eliminate the differences in price levels between countries. PPP conversion factors were obtained from the OECD Stat database [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
<sec id="Sec3">
<title>Search strategy</title>
<p id="Par12">The online databases PubMed and MEDLINE as well as the Cochrane Library were searched using the search string <italic>“TSC OR tuberous sclerosis complex AND (burden of illness OR BOI OR health care use OR health care utilization OR health care utilisation OR resource use OR resource utilization OR resource utilisation OR economic burden OR health burden OR health care costs OR costs OR disease-adjusted life years OR DALY OR quality-adjusted life years OR QALY OR quality of life)”</italic>. Additionally, we searched using the following PubMed medical subject heading (MeSH) terms: <italic>(“Tuberous Sclerosis/economics”[Mesh] OR “Tuberous Sclerosis/epidemiology”[Mesh] OR “Tuberous Sclerosis/statistics and numerical data”[Mesh])</italic>. In addition, the references of included studies were scanned to identify further suitable articles. We restricted the analysis to articles published in indexed, peer-reviewed, journals until October 2019 and which were available through usual library services such as digital and printed records and repositories. Only studies written in English were included in the final evaluation. The last search was performed on October 17, 2019.</p>
<p id="Par13">All studies were screened for eligibility. The initial search returned a total of 605 papers (359 by using PubMed keywords, 245 by using MEDLINE MeSH terms, and one by using the Cochrane keyword search). An additional 12 papers were found by searching the literature references, for a total of 617 papers. Following the removal of 31 duplicates (including the single paper found through the Cochrane search), 586 papers remained. The titles and abstracts of the remaining studies were screened and 341 studies were removed, as they were deemed to be not within the general scope of this review. The remaining 245 studies were evaluated based on the details of their respective full texts. Of those, 212 papers were eventually removed based on not reporting at least one BOI measure (see Fig. <xref ref-type="fig" rid="Fig1">1</xref> for details). In total, 33 studies were included in the systematic part of this review.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Results from the systematic literature search according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines</p></caption><graphic id="MO1" xlink:href="13023_2019_1258_Fig1_HTML"></graphic></fig></p>
<p id="Par14">Of note, merging absolute patient numbers from different studies is challenging because of a possible overlap of individuals, especially in studies recruiting individuals from similar sources, such as patient support groups or studies from the same groups or countries.</p>
</sec>
</sec>
<sec id="Sec4">
<title>Results</title>
<sec id="Sec5">
<title>Organ manifestations</title>
<p id="Par15">Individuals with TSC experience a variety of organ manifestations. The following paragraphs give a non-systematic clinical overview of TSC manifestations as a basis for further description of the specific BOI in TSC. For specifics on the manifestations, please refer to Table <xref ref-type="table" rid="Tab1">1</xref>. For a graphic overview, please refer to Fig. <xref ref-type="fig" rid="Fig2">2</xref>. Wherever possible, we refer to systematic reviews for certain manifestations.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Prevalence of common clinical manifestations in TSC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinical category</th><th>Prevalence</th><th>Clinical Notes</th></tr></thead><tbody><tr><td colspan="3">Neurological manifestations</td></tr><tr><td> Epilepsy</td><td>83.5–88.4% [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]</td><td><p>The prevalence rate (32.9%, 35.9%) of pharmacoresistant epilepsy is similar to general population with focal epilepsy [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p>A mutation in the <italic>TSC2</italic> gene is a risk factor for infantile spasms (47.3% vs. 23% with TSC1 in TOSCA) as well as an earlier manifestation of epilepsy, a higher seizure frequency, and pharmacological refractoriness [<xref ref-type="bibr" rid="CR28">28</xref>].</p></td></tr><tr><td> Epileptic spasms</td><td>38–49% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]</td><td>Most children with TSC and West syndrome develop symptomatic generalized epilepsy (62%) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</td></tr><tr><td> Cortical tubers</td><td>88.2% [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]</td><td></td></tr><tr><td> Subependymal nodules (SEN)</td><td>78.2% [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]</td><td></td></tr><tr><td> Subependymal giant cell astrocytoma (SEGA)</td><td>24.4% [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</td><td><p>SEGAs arise from serially growing SEN, are often greater than 1 cm in diameter, and are generally located near the foramina of Monro [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>While SEGAs generally have a low incidence after adolescence, SEGA growth affected 21–29% past the second decade of life [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] in two studies.</p></td></tr><tr><td colspan="3">Neuropsychiatric manifestations (TSC-associated neuropsychiatric disorders [TAND])</td></tr><tr><td> Intellectual disability</td><td>53.6–65% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>]</td><td><p>Joinson et al. [<xref ref-type="bibr" rid="CR38">38</xref>] described a bimodal distribution of intellectual impairment in TSC. About two-thirds of the studied individuals had an intelligence quotient (IQ) in the normal range, albeit with an overall negative shift (mean IQ: 93), while 31% had a profound intellectual disability [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Individuals with severe intellectual disability due to TSC have higher levels of verbal disability that do those with severe intellectual disability from other causes [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Many individuals with TSC have more than one neuropsychiatric disorder [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></td></tr><tr><td> Autism</td><td>25–61% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">42</xref>–<xref ref-type="bibr" rid="CR47">47</xref>]</td><td>Intellectual impairment and the presence of infantile spasms are associated with higher risks for both autism and ADHD [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</td></tr><tr><td> Attention-deficit hyperactivity disorder (ADHD)</td><td>19.6–30% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]</td><td></td></tr><tr><td> Behavioral problems</td><td><p>Overactivity 45% [<xref ref-type="bibr" rid="CR50">50</xref>]</p><p>Impulsivity 42.7% [<xref ref-type="bibr" rid="CR50">50</xref>]</p><p>Severe aggression 24.3% [<xref ref-type="bibr" rid="CR50">50</xref>]</p><p>Sleep issues 43.9% [<xref ref-type="bibr" rid="CR50">50</xref>]</p></td><td><p>Rates of self-injury and aggression in adults with TSC with intellectual disability: 31 and 37.9%, respectively [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p>In TOSCA, significantly higher rates of overactivity and impulsivity were seen in children; in adults, higher rates of anxiety, depressed mood, mood swings, obsessions, psychosis and hallucinations were reported [<xref ref-type="bibr" rid="CR50">50</xref>]</p><p>The relationship between cortical tubers and autism spectrum disorders is mediated by general cognitive impairment [<xref ref-type="bibr" rid="CR52">52</xref>].</p></td></tr><tr><td> Depression</td><td>23.4–56% [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>–<xref ref-type="bibr" rid="CR55">55</xref>]</td><td><p>A UK study [<xref ref-type="bibr" rid="CR42">42</xref>] showed that the depression rate among patients with TSC was not higher than that in a matched general population comparator cohort.</p><p>A United States (US) study reported that individuals with TSC had significantly higher depressive symptom scores as compared with the general population (11.6 vs. 5.1 on the Hamilton Depression Inventory—short form) [<xref ref-type="bibr" rid="CR56">56</xref>]. Depending on the scoring system used, 19% (Hospital Anxiety and Depression Scale; HADS) to 43% (Symptom Checklist-90-Revised) of adults with TSC present elevated depression scores [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p><p> A study identified HADS scores suggesting anxiety in 56% of adult individuals with TSC [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>A study on individuals with TSC in transition from pediatric treatment found frequent sadness and depression in 60% of patients and high anxiety in 40% [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p>Chung et al. [<xref ref-type="bibr" rid="CR40">40</xref>] demonstrated in a retrospective analysis that behavioral problems and mood disorders can be successfully treated medically in about two-thirds of afflicted individuals.</p></td></tr><tr><td colspan="3">Renal manifestations</td></tr><tr><td> Angiomyolipoma (AML)</td><td>51.8% [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td><p>Recent publications from the TOSCA registry [<xref ref-type="bibr" rid="CR57">57</xref>] have hinted at an even higher rate of AML than previously known (51.8% of 2216 individuals) and suggest an earlier onset in early childhood.</p><p>A retrospective, longitudinal Dutch cohort study in 369 individuals with TSC and chronic kidney disease (CKD) or angiomyolipoma of the kidneys reported that during follow-up, 16% of patients achieved CKD stage 3 or higher [<xref ref-type="bibr" rid="CR35">35</xref>]. A strong association between age, AML size, and CKD was observed. In a UK study [<xref ref-type="bibr" rid="CR42">42</xref>], CKD (stages 3–5) was found more frequently in individuals with TSC of all ages than in the general population at the same age intervals. Of note, a peak in the patients over 65 years cohort (42%) was noted.</p></td></tr><tr><td> Renal cell carcinoma</td><td>1–2% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]</td><td><p>Incidence is similar compared to the general population.</p><p>Renal cell carcinoma can manifest earlier than in the general population, even in children and young adults.</p></td></tr><tr><td> TSC renal cystic kidney disease</td><td><p>Total 50% [<xref ref-type="bibr" rid="CR60">60</xref>]</p><p>Severe (Polycystic kidney disease, PKD) 3.5% [<xref ref-type="bibr" rid="CR21">21</xref>]</p></td><td><p>PKD is a rare manifestation in TSC. The PKD1 gene is situated next to the <italic>TSC2</italic> gene on chromosome 16, so in rare cases a contiguous gene syndrome with severe polycystic kidney disease and early loss of renal function can develop in individuals with TSC.</p><p>Milder, typically asymptomatic forms of TSC renal cystic disease without a certain link to PKD mutations are more common, more commonly in individuals with <italic>TSC2</italic> mutations [<xref ref-type="bibr" rid="CR61">61</xref>].</p></td></tr><tr><td colspan="3">Pulmonary manifestations</td></tr><tr><td> Lymphangioleiomyomatosis (LAM)</td><td>34–81% of female individuals [<xref ref-type="bibr" rid="CR62">62</xref>], rare in males</td><td><p>A Dutch study [<xref ref-type="bibr" rid="CR62">62</xref>] identified LAM-typical cysts in 52 (28%) of 186 individuals with TSC. Pulmonary cysts were detected much more frequently in females (42%), but also in 13% of males [<xref ref-type="bibr" rid="CR62">62</xref>]. In general, however, cysts were larger and more numerous in women than in men. Also, considerable cystic changes were detected almost exclusively in women (in 33 women versus in three men).</p><p>Another study found LAM prevalence increasing rates in women with age (27% at the age of 21 years and 81% at the age of 40 years and older) [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p>A long-term LAM register study from the US showed 26 deaths and 43 lung transplantations occurred over a follow-up of 13 to 17 years in 217 patients. Diagnosis after menopause and better baseline lung function decreased transplantation probability or risk of death. Of note, only 36 of 217 patients had TSC-LAM. The presence of TSC-LAM did not significantly affect time to transplantation or death.</p></td></tr><tr><td colspan="3">Cardiac manifestations</td></tr><tr><td> Cardiac rhabdomyoma</td><td>34–58% [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>Rhabdomyoma in TSC are typically, but not exclusively, multifocal.</td></tr><tr><td> Aortic aneurysm</td><td></td><td>Rare, but can develop from early age [<xref ref-type="bibr" rid="CR64">64</xref>].</td></tr><tr><td colspan="3">Cutaneous manifestations</td></tr><tr><td> Hypopigmented macules (“Ash-leaf spots”)</td><td>66.7–97.2% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td><td><p>Detection can be eased by Wood light in persons with a light skin tone.</p><p>Hypopigmented macules more rarely manifest as “Confetti-like” lesions (2.8% [<xref ref-type="bibr" rid="CR65">65</xref>]).</p></td></tr><tr><td> Angiofibromas</td><td>57.3–74.5% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td><td>Usually appear from the 2nd to 5th year of life.</td></tr><tr><td> Chagrin patches</td><td>22.7–48.1% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td><td>Connective tissue hamartoma, mostly on dorsal body surfaces such as the lower back region.</td></tr><tr><td> Molluscum fibrosum pendulans</td><td>22.6% [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td></td></tr><tr><td> Forehead plaque</td><td>18.9% [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td></td></tr><tr><td> Periungual fibromas</td><td>15.1% [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td>Usually appear first in childhood/adolescence.</td></tr><tr><td colspan="3">Ocular manifestations</td></tr><tr><td> Retinal hamartomas</td><td>30–44% [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]</td><td></td></tr><tr><td> Chorioretinal hypopigmentation</td><td>39% [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td></td></tr><tr><td colspan="3">Other organ manifestations</td></tr><tr><td> Hepatic (hepatic AML, hepatic cysts)</td><td>9.1% [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td>Associated with renal AML [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. These were found in 9.1% of individuals in TOSCA.</td></tr><tr><td> Pancreatic neuroendocrine tumors</td><td>4.1% [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td></td></tr></tbody></table></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Graphical overview of clinical organ manifestations in Tuberous Sclerosis Complex (TSC). Prevalences are given in parentheses after each manifestation. *Prevalence of LAM is given for female patients as there is a high gender-dependency. Prevalences for the majority of manifestations change with age. For sources of the prevalences, please refer to section 3.1 of the manuscript. ADHD = attention deficit hyperactivity disorder, AML = angiomyolipoma, LAM = lymphangioleiomyomatosis, PNET = pancreatic neuroendocrine tumor, SEGA = subependymal giant astrocytoma, SEN = subependymal nodules. Graphic adapted from “Female_shadow_template.svg” and “Girl_diagram_template.svg”, available in the public domain and accessible at <ext-link ext-link-type="uri" xlink:href="https://commons.wikimedia.org/wiki/Human_body_diagrams">https://commons.wikimedia.org/wiki/Human_body_diagrams</ext-link> (original author: Mikael Häggström)</p></caption><graphic id="MO2" xlink:href="13023_2019_1258_Fig2_HTML"></graphic></fig></p>
<sec id="Sec6">
<title>Neurological manifestations</title>
<p id="Par16">Epileptic seizures are a hallmark of TSC and the most common clinical manifestation. The majority of individuals (83.6%) in the multinational Tuberous Sclerosis Registry to Increase Disease Awareness (TOSCA) [<xref ref-type="bibr" rid="CR20">20</xref>] had a diagnosis of epilepsy [<xref ref-type="bibr" rid="CR21">21</xref>]. Prevalence can depend upon patients’ age and the extent of cerebral lesions. In general, seizures in patients with TSC are often detected before the third year of life<sup>,</sup> [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], but can also develop for the first time in adulthood (up to 12% of cases). The most common seizure type in TSC are localization-related or focal seizures (67.5%), followed by epileptic (“infantile”) spasms in 38 to 49% [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] of individuals with TSC: Epileptic spasms typically begin between 4 and 8 months of age and later transform into other seizure types; they define West syndrome, a severe epileptic encephalopathy which is common in children with TSC. The majority of individuals with TSC characterized in the TOSCA registry had cortical tubers (88.2%) or subependymal nodules (SEN; 78.2%). Subependymal giant cell astrocytomas (SEGAs) were found in 24.4% of the TOSCA population. SEGA can obstruct the intraventricular space and lead to noncommunicating hydrocephalus requiring surgery (22.4% of those with SEGA in TOSCA) or shunt placement 4.1%) [<xref ref-type="bibr" rid="CR21">21</xref>]. For a review on neurological manifestations of TSC, please see Lu et al. [<xref ref-type="bibr" rid="CR70">70</xref>].</p>
</sec>
<sec id="Sec7">
<title>Neuropsychiatric manifestations</title>
<p id="Par17">Cognitive, psychiatric, and neurodevelopmental problems are common in TSC, with one of these affecting almost all individuals with TSC at some point in their life. These different manifestations are grouped under the term “TSC-associated neuropsychiatric disorders” (TAND). Data from the TOSCA registry [<xref ref-type="bibr" rid="CR21">21</xref>] revealed that 54.9% of persons with TSC had some level of intellectual disability (50 to 65% in prior studies [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>]), with good agreement present between caregiver-reported and psychometric results. Generally, severe forms of intellectual disability are overrepresented in TSC [<xref ref-type="bibr" rid="CR71">71</xref>]. Besides epileptic spasms, a prior history of seizures, greater seizure frequency, earlier seizure onset, and pharmacoresistant epilepsy all correlated with greater likelihood of developmental disabilities [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR72">72</xref>–<xref ref-type="bibr" rid="CR75">75</xref>]. Conversely, early seizure control improves the odds of a better cognitive outcome [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. TSC is one of the disorders most strongly connected with autism [<xref ref-type="bibr" rid="CR78">78</xref>]. Rates of autism in individuals with TSC range up to 61% in smaller studies [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Attention deficit hyperactivity disorder (ADHD) affects about 20–30% of individuals with TSC. On a behavioral level, the most common problems are, repetitive or disruptive behavior (13–56%) [<xref ref-type="bibr" rid="CR45">45</xref>] and sleep issues (up to 60%) [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Children with an intellectual disability are more likely to also exhibit behavioral problems, autism, ADHD, and speech difficulties [<xref ref-type="bibr" rid="CR36">36</xref>]. Of note, a relevant proportion (about 30%) of intellectually unaffected children with TSC also exhibit behavioral disorders [<xref ref-type="bibr" rid="CR36">36</xref>] or specific cognitive defects [<xref ref-type="bibr" rid="CR80">80</xref>]. In a UK study [<xref ref-type="bibr" rid="CR23">23</xref>], depression was diagnosed in about a quarter (23.4%) of adult patients. Individuals with TSC may also be more susceptible to stress-related disorders such as posttraumatic stress disorder [<xref ref-type="bibr" rid="CR81">81</xref>]. The presence of a high proportion of missing data in the TOSCA-registered individuals suggests that TAND are in fact insufficiently diagnosed [<xref ref-type="bibr" rid="CR21">21</xref>]. The use of a standardized TAND checklist is encouraged to improve the assessment of neuropsychiatric symptoms in TSC on, at minimum, a yearly basis [<xref ref-type="bibr" rid="CR82">82</xref>]. For a succinct overview of TAND, please see Curatolo et al. [<xref ref-type="bibr" rid="CR71">71</xref>], and for a recent review based on the TOSCA registry, please see de Vries et al. [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
</sec>
<sec id="Sec8">
<title>Renal manifestations</title>
<p id="Par18">Renal angiomyolipomas (AML) occur in about one-half to two-thirds of individuals with TSC [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR83">83</xref>–<xref ref-type="bibr" rid="CR85">85</xref>]. They are believed to typically appear first in childhood and then tend to grow during adolescence and into adulthood [<xref ref-type="bibr" rid="CR42">42</xref>]. The main complication of AML is retroperitoneal hemorrhage, which can be fatal due to the associated blood loss. The risk is greater as the tumors become larger. AML with a greatest diameter of more than 3 cm are frequently associated with dysplastic, aneurysmal blood vessels and carry an especially large bleeding risk. Other complications of AML may include pain, renal insufficiency, and arterial hypertension [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. The lifetime risk for renal hemorrhage ranges from 20% in women to 10% in men [<xref ref-type="bibr" rid="CR87">87</xref>]. TSC renal cystic disease is seen in about half of individuals with TSC by MRI. Premature reduction of renal function affects almost half of individuals with TSC and is due to TSC renal cystic disease in addition to AML complications [<xref ref-type="bibr" rid="CR60">60</xref>]. The risk of end-stage renal failure is presumed to be 1% in TSC [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>] and chronic kidney disease is an independent risk factor of cardiovascular diseases. Renal cell carcinoma (RCC) develops in about 2–4% of persons with TSC with a rate comparable to the general population [<xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR59">59</xref>]. RCC can however manifest earlier than in the general population. For a comprehensive review of TSC renal manifestations, please refer to Bissler and Kingswood [<xref ref-type="bibr" rid="CR60">60</xref>].</p>
</sec>
<sec id="Sec9">
<title>Pulmonary manifestations</title>
<p id="Par19">Lymphangioleiomyomatosis (LAM) is the primary pulmonic manifestation of TSC and almost exclusively affects adult females. The first diagnosis of LAM usually occurs around the end of the third decade of life, but insufficient diagnosis is a common problem in TSC-associated and spontaneous LAM [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. TSC-associated LAM can have very different consequences for the individual, ranging from radiological findings without clinical relevance to recurrent pneumothoraces with increased morbidity (hospital stays, pleurodesis or other operations) up to progressive loss of lung function. A US study found a prevalence of 34% among 38 women with TSC (mean age: 38 years; age range not given) who had no prior history of LAM.</p>
</sec>
<sec id="Sec10">
<title>Cardiac manifestations</title>
<p id="Par20">Cardiac rhabdomyoma (CR) is one of the earliest clinical signs of TSC and can lead to a prenatal diagnosis of TSC on ultrasound [<xref ref-type="bibr" rid="CR90">90</xref>]. In TOSCA, 34.3% of individuals had had CR. In a small study involving only 11 children [<xref ref-type="bibr" rid="CR91">91</xref>], about one-third of the CR cases spontaneously regressed, and the CRs were rarely symptomatic (5.6% with arrhythmia/dysrhythmia and 2.9% with valve dysfunction). In another small study [<xref ref-type="bibr" rid="CR92">92</xref>], TSC was diagnosed almost in all individuals who had a postnatal diagnosis of CR (<italic>n</italic> = 25), while either partial or complete regression was found in almost all children (96%). The authors suggested a likelihood of 79% for a TSC diagnosis later in life for individuals receiving a prenatal diagnosis of CR. Another small study [<xref ref-type="bibr" rid="CR93">93</xref>] (<italic>n</italic> = 18) estimated this likelihood at 39%.</p>
</sec>
<sec id="Sec11">
<title>Cutaneous manifestations</title>
<p id="Par21">Skin manifestations in TSC appear in nearly all individuals with TSC and can take many forms [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. Hypomelanotic macules (also seen in the form of larger “ash-leaf spots” or widespread “confetti macules”) are usually the first skin manifestation of TSC and appear in the majority of individuals with the disorder (prevalence of 66.7% in TOSCA), often at birth. Facial angiofibromas (AF) (prevalence of 57.3% in TOSCA) generally manifest in the first years of life (mean age of 6 years in TOSCA) and thereafter tend to grow. Less common are chagrin patches (prevalence of 22.7% in TOSCA), forehead plaques, and subungual fibromas. A US study [<xref ref-type="bibr" rid="CR56">56</xref>] reported TSC-typical skin manifestations in 77% of children and 44% of adults. Enamel deficits are also common in TSC and can aid with clinical diagnosis [<xref ref-type="bibr" rid="CR95">95</xref>].</p>
</sec>
<sec id="Sec12">
<title>Ocular manifestations</title>
<p id="Par22">Retinal hamartomas are the most typical ocular manifestation of TSC. These are mostly asymptomatic, but can rarely impair vision. Generally, 30 to 40% of individuals with TSC are assumed to be impacted by hamartomas [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], with <italic>TSC2</italic> mutations conferring a particularly higher risk [<xref ref-type="bibr" rid="CR96">96</xref>]. Further manifestations are achromatic patches (see Table <xref ref-type="table" rid="Tab1">1</xref>).</p>
</sec>
<sec id="Sec13">
<title>Other organ manifestations</title>
<p id="Par23">Usually asymptomatic hepatic manifestations (i.e., AML, cysts) are known in TSC [<xref ref-type="bibr" rid="CR67">67</xref>] and are associated with renal AML [<xref ref-type="bibr" rid="CR68">68</xref>]. These were found in 9.1% of individuals in TOSCA. Pancreatic neuroendocrine tumors, while overall rare (9/219; 4.1% in one study [<xref ref-type="bibr" rid="CR69">69</xref>]), remain the most common pancreatic neoplasia in individuals with TSC [<xref ref-type="bibr" rid="CR69">69</xref>]. Many more manifestations have been reported, such as sclerotic bone lesions [<xref ref-type="bibr" rid="CR97">97</xref>] and cerebellar lesions in individuals with a TSC2 mutation [<xref ref-type="bibr" rid="CR98">98</xref>] (see Table <xref ref-type="table" rid="Tab1">1</xref>). The full scope of manifestations is however out of the scope of this non-systematic clinical overview.</p>
<p id="Par24">In general, clinical hamartoma manifestations share a typical set of dynamics throughout an individual’s life. CRs, hypomelanotic macules, and seizures (and, in succession, SEN and cortical tubers) are often diagnosed in the first months or first years after birth. SEGA prevalence is highest during childhood. AML as well as some skin manifestations such as facial AF or chagrin patches appear in childhood, and data from TOSCA shows that their prevalence continues to increase into adulthood, while LAM and ungual fibromas are rarely diagnosed before adolescence. Cases of LAM are typically diagnosed at around 30 to 40 years of age in females.</p>
</sec>
</sec>
<sec id="Sec14">
<title>Burden of illness and resource use</title>
<p id="Par25">Determining the burden of illness (BOI) of a disease requires summarizing its impact on the individual and society, while evaluating the use of health care resources (HCRU), morbidity, mortality, direct and indirect costs and individual and caregiver quality of life [<xref ref-type="bibr" rid="CR18">18</xref>]. BOI can be expressed in health summary scores such as “disease-adjusted life years” (DALY), that represent years lost to disease from healthy life or “quality-adjusted life years” (QALY), which represents a compound of gained life expectancy and life quality in the setting of an interventional study (e.g. new drug). These measures do not reflect BOI on an individual level. On the ecnomic level, BOI consists of (1) direct costs to the health care system such as inpatient treatments or medications and (2) indirect costs due to a loss of productivity such as days off work, reduced working hours, or a job loss for the individual or caregivers. On an individual level, factors such as pain or discomfort or psychological stress of caregivers are included in quality of life measures. TSC’s wide phenotypic variety and changing clinical course throughout life leads to heterogeneous study cohorts with heterogeneous clinical manifestations. Thus, a complete evaluation of the BOI in TSC requires the assessment of a multitude of organ manifestations, making studies on BOI in TSC challenging to perform. Differences in health care accessibility and general organization of the health care system also hinder the aggregation of study results. Recently, de Vries et al. demonstrated that three health-related quality of life measures—the “Quality of Life in Childhood Epilepsy” (QOLCE), the “Quality of Life in Epilepsy Inventory for Adolescents-48” (QOLIE-AD-48), and the “Quality of Life in Epilepsy Inventory-31-Problems” (QOLIE-31-P) surveys—are largely applicable to individuals with TSC [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
<p id="Par26">A total of 33 papers presented any data on BOI in TSC (Table <xref ref-type="table" rid="Tab2">2</xref> and Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Of these, 21 papers report health care resource use [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR104">104</xref>–<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. Direct costs are reported by 10 studies [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR119">119</xref>] and four studies assessed drivers of direct cost [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. The measures of DALY and QALY were only used by one study that calculated projected costs of different treatment strategies for epilepsy in TSC [<xref ref-type="bibr" rid="CR109">109</xref>]. Fourteen studies reported on quality of life [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>–<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. Nine studies (also) reported BOI for caregivers [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR125">125</xref>] (five studies reported analyses of the same population or subgroups of the same). A total of 16 different questionnaires were used in individuals with TSC, none in more than four studies. In caregivers, six different questionnaires were used, not more than three in one study. The QOLCE and QOLIE were used in one study each [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Please refer to Table <xref ref-type="table" rid="Tab2">2</xref> for details.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Overview of studies reporting burden of illness by health care resource use, direct costs or mortality in TSC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Type of study and data approach</th><th>Data source/ country of patient origin</th><th>Cohorts</th><th>Organ systems</th><th>Incl. / excl. Criteria</th><th>N total</th><th>N caregiver</th><th>Evaluated period (year)</th><th>Duration time (years)</th><th>Actual time evaluated (years)</th><th>Mean age</th><th>Mean age adults</th><th>Mean age children</th><th>N female (%)</th><th>N children (%)</th><th>Percentage caregiver</th><th>HRCU - inpatient</th><th>HRCU - outpatient</th><th>Direct costs</th><th>Cost drivers (regression analysis)</th><th>Social costs</th><th>Mortality</th><th>Individual BOI</th><th>Caregiver BOI</th></tr></thead><tbody><tr><td>Shepherd et al. 1991 [<xref ref-type="bibr" rid="CR100">100</xref>]</td><td>Retrospective chart review, bottom-up</td><td>Mayo Clinic/ USA</td><td>all TSC</td><td>all</td><td>Clinical diagnosis of TSC according to 1988 Gomez criteria</td><td>355</td><td>0</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via mortality</td><td>n. r.</td></tr><tr><td>Liang et al. 2019 [<xref ref-type="bibr" rid="CR101">101</xref>]</td><td>Prospective, single-center</td><td>Capital Epilepsy Therapy Center Beijing/ China</td><td>TSC + E</td><td>all</td><td>Pharmacoresistant epilepsy, surgery in year 2007</td><td>25</td><td>N/A</td><td>2007</td><td>1</td><td>1</td><td>14.3 (R 6–23)</td><td>n. r.</td><td>n. r.</td><td>8 (32)</td><td>100</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Quality of life in epilepsy inventory-31 (QOLIE-31)</td><td>n. r.</td></tr><tr><td>Lennert et al. 2012 [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>Retrospective chart review, bottom-up</td><td>Minnesota Epilepsy Group/ USA</td><td>only TSC + E</td><td>all</td><td><p>Inclusion: TSC–related seizure disorder within the first 6 months after tuberous sclerosis complex diagnosis</p><p>exclusion: TSC–unrelated seizure disorder</p></td><td>95 (only children)</td><td>0</td><td>1973–2010</td><td>37</td><td>0.5 to 5</td><td>3.1 (SD 7.8)</td><td>N/A</td><td>3.1 (SD 7.8)</td><td>48 (51.0)</td><td>91 (95.8)</td><td>N/A</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>only via clinical information and HCRU</td><td>n. r.</td></tr><tr><td>Graffigna et al. 2013 [<xref ref-type="bibr" rid="CR102">102</xref>]</td><td>Qualitative interview</td><td>survey of patients from 15 TSC centers/ Italy</td><td>Caregivers of children with TSC + SEGA</td><td>all</td><td>Caregivers of children with TSC + SEGA</td><td>0</td><td>48</td><td>2011–2012</td><td>1</td><td>N/A</td><td>47 (SD 6.3) (caregiver)</td><td>N/A</td><td>N/A</td><td>62.5 (caregiver)</td><td>N/A</td><td>100</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Qualitative statements</td></tr><tr><td>Krueger et al. 2013 [<xref ref-type="bibr" rid="CR103">103</xref>]</td><td>Prospective, multicenter,open-label, phase!/ II clinical trial</td><td>TSC clinics at Cincinnati Children’s Hospital Medical Center (CCHMC) and Texas Children’s Hospital/ USA</td><td>Pharmacoresistant epilepsy</td><td>brain</td><td>&gt; = 2 years of age, confirmed diagnosis of TSC (1998 clinical diagnostic criteria or identified disease-causing mutation, pharmacoreistant epilepsy)</td><td>23</td><td>N/A</td><td></td><td>16 months</td><td>16 months</td><td>8 (R 2–21)</td><td>n. r.</td><td>n. r.</td><td>50</td><td>n. r.</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Quality of Life for Children with Epilepsy (QOLCE), Nisonger Child Behavioral Rating Form (NCBRF)</td><td>n. r.</td></tr><tr><td>Eijkemans et al. 2015 [<xref ref-type="bibr" rid="CR86">86</xref>]</td><td>Retrospective observational, bottom-up</td><td>University Medical Center Utrecht (UMCU)/ Netherlands</td><td>all TSC/ TSC + AML</td><td>kidney</td><td>Diagnosis of TSC according to the modified Gomez criteria and aged 18 years or older</td><td>351<sup>*</sup> (only adults)</td><td>0</td><td>1990–2012</td><td>22</td><td>median 15.8</td><td>39.8 (R 18–89)</td><td>39.8 (R 18–89)</td><td>N/A</td><td>175 (49.8)</td><td>N/A (0)</td><td>N/A</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Kristof et al. 2015 [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td>Retrospective cohort study, top-down</td><td>Régie de l’Assurance-Maladie du Québec (RAMQ; Quebec Health Care Insurance Board) database/ Canada</td><td>all TSC/ TSC + LAM/ LAM/ controls</td><td>lung</td><td>LAM and/or TSC and controls</td><td>1004 (children and adults)</td><td>0</td><td>1996–2011</td><td>15</td><td>n. r.</td><td>39.5 (SD 24.4)</td><td>n. r.</td><td>n. r.</td><td>555 (55.3)</td><td>n. r.</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Rentz et al. 2015a [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>Cross-sectional, non-interventional, bottom-up</td><td>web-based survey/ USA</td><td>paediatric/ adult TSC patients/ caregivers</td><td>all</td><td><p>Inclusion: age 18 years or older, TSC diagnosis (or care for individual with TSC), read English and ability to participate, and consent</p><p>exclusion: patients with cognitive impairment or other health impairment that interfere w/ survey completion</p></td><td>676<sup>**</sup> (children and adults)</td><td>275 (179 adult caregiver, 96 pediatric caregiver)</td><td>2012</td><td>N/A</td><td>2 months (May and June 2012)</td><td>29.8 (SD 17.7)</td><td>38 (SD 12.8)</td><td>7.1 (SD 4.6)</td><td>400 (59.2)</td><td>197 (26.5)</td><td>40.7</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Short Form (12) Health Survey (SF-12), Hamilton Depression Rating Scale-Short Form (HDI-SF)</td><td>SF-12,HDI-SF</td></tr><tr><td>Rentz et al. 2015b [<xref ref-type="bibr" rid="CR105">105</xref>]</td><td>Cross-sectional, non-interventional, bottom-up</td><td>web-based survey/ USA</td><td>TSC caregivers</td><td>all</td><td>See Rentz et al. 2015a</td><td>275<sup>**</sup> (children and adults)</td><td>275<sup>**</sup></td><td>2012</td><td>0</td><td>2 months (May and June 2012)</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>217 (79)</td><td>0</td><td>100</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>SF-12, HDI-SF</td><td>SF-12, HDI-SF</td></tr><tr><td>Skalicky et al. 2015 [<xref ref-type="bibr" rid="CR106">106</xref>]</td><td>Cross-sectional, non-interventional, bottom-up</td><td>web-based survey/ USA</td><td>paediatric/ adult TSC patients</td><td>all</td><td>See Rentz et al. 2015 a</td><td>116<sup>**</sup> (children and adults)</td><td>69<sup>**</sup></td><td>2012</td><td>0</td><td>2 months (May and June 2012)</td><td>25.5 (SD 16.6)</td><td>36.8 (SD 11.5)</td><td>9 (SD 5.0)</td><td>n. r.</td><td>47 (40.5)</td><td>59.5</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>SF-12, HDI-SF, Work Productivity and Activity Impairment plus Classroom Impairment Questions: Special Health Problem (WPAI CIQ-SHP), version 2</td><td>SF-12, HDI-SF, WPAI CIQ-SHP-version 2</td></tr><tr><td>Sun et al. 2015 [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td>Retrospective cohort study, top-down</td><td>National claims databases (MarketScan commercial and Medicaid, Pharmetrics commercial)/ USA</td><td>all TSC + SEGA surgery</td><td>brain (SEGA)</td><td>TSC patients with first SEGA surgery claim in study period</td><td>47 (children and adults)</td><td>0</td><td>2000–2011</td><td>11</td><td>n. r.</td><td>11.6</td><td>n. r.</td><td>n. r.</td><td>16 (34)</td><td>n. r.</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Vekeman et al. 2015 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td>Retrospective, longitudinal cohort study, bottom-up</td><td>University Medical Center Utrecht (UMCU)/Netherlands</td><td>CKD stage/ AML size</td><td>kidney, lung</td><td>Diagnosis of TSC according to the revised 1998 TSC criteria</td><td>369<sup>*</sup> (children and adults)</td><td>0</td><td>1990–2012</td><td>22</td><td>mean 14.3</td><td>32.4 (SD 23.7) CKD stage I</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>only via clinical information and HCRU</td><td>n. r.</td></tr><tr><td>Crall et al. 2016 [<xref ref-type="bibr" rid="CR108">108</xref>]</td><td>Cross-sectional, bottom-up</td><td>web-based survey and survey of out-patients/USA</td><td>TSC with AF and caregivers</td><td>skin</td><td>Inclusion: clinical or genetic diagnosis of TSC, age &gt; 6 years at enrollment /caregiver of a patient exclusion: uncertain diagnosis of TSC/ severe neurologic deficits/ survey noncompletion</td><td>219 (children and adults)</td><td>161</td><td>2014–2015</td><td>N/A</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>94 (42.9)</td><td>n. r.</td><td>73.5</td><td>n. r.</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Children’s Dermatology Life Quality Index (CDLQI)</td><td>Childhood Atopic Dermatitis Impact Scale (CADIS)</td></tr><tr><td>Fallah et al. 2016 [<xref ref-type="bibr" rid="CR109">109</xref>]</td><td>Cost-utility analysis, bottom-up and top-down</td><td>literature search (clinical data), Tufts CEA registry, Agency for Healthcare Research and Quality (AHRQ) Medical Expenditure Panel Survey/ USA</td><td>TSC + E only (model)</td><td>brain (seizures)</td><td>N/A</td><td>N/A</td><td>N/A</td><td>2000–2015</td><td>15</td><td>15 for clinical outcomes, cost data updated to 2016 USD</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A (100)</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td></tr><tr><td>Kingswood et al. 2016a [<xref ref-type="bibr" rid="CR110">110</xref>]</td><td>Retrospective cohort study, bottom-up and top-down</td><td>National Health Service (NHS) databases CPRD (clinical practice research datalink) and CPRD-HES (hospital event statistics)/ UK</td><td>all TSC/ general population comparator</td><td>all</td><td>Diagnosis of TSC between 1 January 1987 and 30 June 2013 and at least 3 years of continuous data prior to the last available record</td><td>278<sup>***</sup> (children and adults)</td><td>0<sup>***</sup></td><td>1987–2013</td><td>26</td><td>at least 3</td><td>31.5 (SD 18.7)</td><td>n. r.</td><td>n. r.</td><td>147 (53)</td><td>n. r.</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Kingswood et al. 2016b [<xref ref-type="bibr" rid="CR111">111</xref>]</td><td>Retrospective cohort study, bottom-up and top-down</td><td>National Health Service (NHS) databases CPRD (clinical practice research datalink) and CPRD-HES (hospital event statistics)/ UK</td><td>TSC + renal manifestations/ general population comparator</td><td>kidney</td><td>See Kingswood et al. 2016a</td><td>79<sup>***</sup> (children and adults)</td><td>0<sup>***</sup></td><td>1987–2013</td><td>26</td><td>at least 3</td><td>38,3 (SD 17.1)</td><td>n. r.</td><td>n. r.</td><td>37 (46.7)</td><td>8 (11.3)</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Kingswood et al. 2016c [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td>Retrospective cohort study, bottom-up and top-down</td><td>National Health Service (NHS) databases CPRD (clinical practice research datalink) and CPRD-HES (hospital event statistics)/ UK</td><td>all TSC/ general population comparator</td><td>all</td><td>Diagnosis of TSC between 1 January 1987 and 30 June 2013</td><td>334<sup>***</sup> (children and adults)</td><td>0<sup>***</sup></td><td>1987–2013</td><td>26</td><td>mean 17.4 (SD 6.4)</td><td>30.3 (SD 18.6)</td><td>n. r.</td><td>n. r.</td><td>177 (53)</td><td>n. r. (29)</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via mortality</td><td>n. r.</td></tr><tr><td>Wilson et al. 2016 [<xref ref-type="bibr" rid="CR112">112</xref>]</td><td>Retrospective, top-down</td><td>Agency for Healthcare Research and Quality (AHRQ) National Inpatient Sample (NIS) database/ USA</td><td>all TSC</td><td>all</td><td>All TSC patients in the database</td><td>5655 (hospital admissions) (children and adults)</td><td>0</td><td>2000–2010</td><td>10</td><td>n. r.</td><td>22.3 (SD 19.5)</td><td>n. r.</td><td>n. r.</td><td>n. r. (52.5)</td><td>n. r.</td><td>N/A</td><td>yes</td><td>n. r.</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Amin et al. 2017 [<xref ref-type="bibr" rid="CR113">113</xref>]</td><td>Retrospective chart review, bottom-up</td><td>Bath TSC clinic database/ UK</td><td>all TSC</td><td>all</td><td>Definite diagnosis of TSC (International TSC Consensus Group)</td><td>284 (children and adults)</td><td>0</td><td>1981–2015</td><td>34</td><td>median 8 (IQR 3–17)</td><td>w/ ID 25 (IQR 15–36), wo/ ID 28 (IQR 17–43)</td><td>n. r.</td><td>n. r.</td><td>142 (50)</td><td>n. r.</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via mortality</td><td>n. r.</td></tr><tr><td>Shepherd et al. 2017 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>Retrospective cohort study, bottom-up and top-down</td><td>National Health Service (NHS) databases (EMR, HES, clinical practice research datalink)/ UK</td><td>all TSC/ TSC + E, TSC + E/ general population comparator</td><td>all</td><td>Recorded diagnosis of TSC in study period and at least 3 years of continuous data prior to the last available record</td><td>209 (children and adults)</td><td>0</td><td>1997–2012</td><td>15</td><td>at least 3</td><td>26.8 (SD 17.8)</td><td>N/A</td><td>N/A</td><td>102 (48.8)</td><td>81 (38.8)</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>only via clinical information and HCRU</td><td>n. r.</td></tr><tr><td>Song X. et al. 2017 [<xref ref-type="bibr" rid="CR114">114</xref>]</td><td>Cross-sectional, top-down</td><td>Truven Commercial Claims and Medicaid database/ USA</td><td>TSC + AML/ controls in Commercial/ Medicaid databases</td><td>all</td><td>Patients diagnosed with TSC-renal AML in the databases</td><td>743 (children and adults)</td><td>0</td><td>2000–2013</td><td>13</td><td>37.0 (SD 31.1) to 87.2 (SD 42.9)</td><td>n. r.</td><td>36.9 (SD 13.0)</td><td>9.7 / 6.9 (SD 5.2)</td><td>n. r.</td><td>256 (34.5)</td><td>N/A</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Welin et al. 2017 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>Retrospective, top-down</td><td>National Board of Health and Welfare (NBHW) national registers/ Sweden</td><td>all TSC</td><td>all</td><td>All patients with TSC diagnosis in national register</td><td>551 (children and adults)</td><td>0</td><td>2004–2014</td><td>10</td><td>mean 8.8</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>339 (45.1)</td><td>238 (61.6) at first observation</td><td>N/A</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Both et al. 2018 [<xref ref-type="bibr" rid="CR115">115</xref>]</td><td>Qualitative study using semistructured interviews</td><td>Dutch Foundation for patients with TSC, healthcare providers/ Netherlands</td><td>TSC patients/ parents</td><td>all</td><td>Adolescent TSC patients 18–30 years old with a definitive TSC diagnosis; parents of children with TSC of 18 years, or older, or younger and having transitioned into adult care</td><td>28 (children and adults)</td><td>12</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>R 17–30</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>TSC-related themes, categorized by the ICF</td><td>TSC-related themes, categorized by the ICF</td></tr><tr><td>Hamer et al. 2018 [<xref ref-type="bibr" rid="CR116">116</xref>]</td><td>Retrospective, multi-center cohort study (12), bottom-up</td><td>survey of patients from 12 German epilepsy centers/ Germany</td><td>all TSC</td><td>all</td><td>Patients aged ≥18 years with a confirmed TSC diagnosis according to clinical Gomez criteria and/or genetic testing</td><td>262 (only adults)</td><td>0</td><td>2010–2015</td><td>5</td><td>5</td><td>36.2 (SD 9)</td><td>36.2 (SD 9)</td><td>N/A</td><td>122 (46.6)</td><td>0</td><td>N/A</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Kopp et al. 2018 [<xref ref-type="bibr" rid="CR117">117</xref>]</td><td>Retrospective observational, bottom-up</td><td>Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital (MGH)/ USA</td><td>all TSC</td><td>all</td><td>All patients under the age of 18 with TSC</td><td>99 (only children)</td><td>0</td><td>2001–2007</td><td>6</td><td>n. r.</td><td>N/A</td><td>7.7 (SD 4.2)</td><td>7.7 (SD 4.2)</td><td>54 (54.5)</td><td>99 (100)</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Symptom Checklist-90—Revised (SCL-90-R), Parenting Stress Index (Short Form)</td></tr><tr><td>Mowrey et al. 2018 [<xref ref-type="bibr" rid="CR118">118</xref>]</td><td>Cross-sectional, bottom-up</td><td>web-based survey/ USA</td><td>all TSC</td><td>all</td><td>Having a diagnosis of TSC, age of 18 years or older, ability to independently complete a 30-min electronic survey.</td><td>71 (only adults)</td><td>0</td><td>2017–2018</td><td>N/A</td><td>3 months</td><td>43.7 (SD 13.2)</td><td>43.7 (SD 13.2)</td><td>N/A</td><td>52 (73)</td><td>0</td><td>N/A</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Brief-Illness Perceptions Questionnaire (Brief-IPQ), Beck Anxiety Inventory (BAI), and Beck Depression Inventory-II (BDI-II).</td><td>n. r.</td></tr><tr><td>Rentz et al. 2018 [<xref ref-type="bibr" rid="CR119">﻿119﻿</xref>]</td><td>Cross-sectional, non-interventional, bottom-up</td><td>web-based survey/USA</td><td>paediatric/ adult TSC + AML patients/ caregivers</td><td>kidney</td><td>see Rentz et al. 2015a</td><td>182<sup>**</sup> (110 AML) (children and adults)</td><td>59<sup>**</sup></td><td>2012</td><td>N/A</td><td>2 months (May and June 2012)</td><td>29.1 (SD 16.6)</td><td>36.4 (SD 13.6)</td><td>10.6 (SD 4.7)</td><td>n. r.</td><td>31 (28.2)</td><td>54</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>SF-12, HDI-SF</td><td>SF-12, HDI-SF</td></tr><tr><td>Skalicky et al. 2018 [<xref ref-type="bibr" rid="CR119">﻿119﻿</xref>]</td><td>Cross-sectional, bottom-up</td><td>web-based survey/ USA</td><td>paediatric/ adult TSC patients/ caregivers</td><td>all</td><td>see Rentz et al. 2015a</td><td>609<sup>**</sup> (children and adults)</td><td>275<sup>**</sup></td><td>2012</td><td>N/A</td><td>2 months (May and June 2012)</td><td>28.9 (SD 18)</td><td>38 (SD 13.1)</td><td>7.1 (SD 4.6)</td><td>n. r.</td><td>179 (29.4)</td><td>45.2</td><td>yes</td><td>yes</td><td>yes</td><td>n. r.</td><td>yes</td><td>n. r.</td><td>WPAI CIQ-SHP version 2</td><td>WPAI CIQ-SHP version 2; out-of-pocket indirect healthcare spending related to time and money spent for TSC-related medical care travel and childcare expenses</td></tr><tr><td>Song J. et al. 2018 [<xref ref-type="bibr" rid="CR120">120</xref>]</td><td>Retrospective, bottom-up and top-down</td><td>National Tuberous Sclerosis Association (NTSA), TSC Natural History Database/ USA, Belgium</td><td>TSC + E only</td><td>all</td><td>All TSC patients in the database</td><td>1110(children and adults)</td><td>0</td><td>2006–2014</td><td>8</td><td>4.3</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>535 (48.2)</td><td>n. r.</td><td>N/A</td><td>yes</td><td>yes</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>only via HCRU</td><td>n. r.</td></tr><tr><td>Amin et al. 2019 [<xref ref-type="bibr" rid="CR121">121</xref>]</td><td>Cross-sectional, non-interventional</td><td>Bath TS clinic/ UK</td><td>All TSC</td><td>all</td><td>TSC, as defined by the International Tuberous Sclerosis Complex Consensus Group</td><td>91</td><td>n. r.</td><td>2014</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>34</td><td>12</td><td>50%</td><td>35 (38.5)</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td><p>Pediatric Quality of Life Inventory (PedsQL) (children)</p><p>SF-36 (adults)</p></td><td>n. r.</td></tr><tr><td>Bar et al. 2019 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td>Cross-sectional, bottom-up</td><td>Written questionnaire/ network of the reference center for rare epilepsies and TSC (Necker-Enfants Malades and university hospitals of Saint-Etienne, Lille and Lyon) and the French association for TSC (ASTB), France</td><td>TSC patients in transition from pediatric care</td><td>all</td><td>Age &gt; 18 years and confirmed diagnosis of TSC before the age of 16</td><td>60 (only adults)</td><td>30</td><td>2014</td><td>N/A</td><td>n. r.</td><td>32 (range 18–55)</td><td>32 (range 18–55)</td><td>N/A</td><td>29 (49%)</td><td>N/A</td><td>50</td><td>yes</td><td>yes</td><td>n.r.</td><td>n.r.</td><td>yes</td><td>n.r.</td><td>Quality of Life Scale (QOLS), Multidimensional Fatigue Inventory-20 (MFI-20)</td><td>n.r.</td></tr><tr><td>Tritton et al. 2019 [<xref ref-type="bibr" rid="CR122">122</xref>]</td><td>Cross-sectional, bottom-up</td><td>Web-based survey/ USA and Europe</td><td>TSC + epilepsy</td><td>all</td><td>Clinical diagnosis of TSC and epilepsy</td><td>186</td><td>N/A</td><td>2017–2018</td><td>N/A</td><td>N/A</td><td>27.3</td><td>n. r.</td><td>n. r.</td><td>82 (44.1)</td><td>70 (37.6)</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>European quality of life (EQ – 5 dimensions – 3 levels)</td><td>n. r.</td></tr><tr><td>Vergeer et al. 2019 [<xref ref-type="bibr" rid="CR123">123</xref>]</td><td>Single-center retrospective chart review, bottom-up</td><td>University Medical Center Utrecht (UMCU)/Netherlands</td><td>TSC with AML, SEGA and/or epilepsy</td><td>all</td><td>Diagnosis of TSC according to the revised 1998 TSC criteria</td><td>363<sup>*</sup></td><td>0</td><td>1990–2015 (2012)</td><td>16</td><td>N/A</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>Health Utility Index version 3 (HUI-3)</td><td>n. r.</td></tr><tr><td>Zak et al. 2019 [<xref ref-type="bibr" rid="CR124">124</xref>]</td><td>Retrospective chart review, bottom-up</td><td>Cincinnati Children’s Hospital Medical Center TSC clinic/ USA</td><td>all TSC</td><td>all</td><td>All patients who attended the CCHMC TSC clinic during the study period, National Death Index (NDI)</td><td>567 (children and adults)</td><td>0</td><td>1998–2016</td><td>18</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>247 (&gt; 18) (%n. r.)</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>yes</td><td>only via mortality</td><td>n. r.</td></tr></tbody></table><table-wrap-foot><p>*, ** and *** denote studies with overlapping cohorts, <italic>AF</italic> facial angiofibroma, <italic>AML</italic> angiomyolipoma, <italic>LAM</italic> lymphangioleiomyomatosis, <italic>R</italic> range, <italic>SD</italic> standard deviation, <italic>SEGA</italic> subependymal giant cell astrocytoma, <italic>TSC+E</italic> TSC+epilepsy</p></table-wrap-foot></table-wrap></p>
<sec id="Sec15">
<title>Health care resource use</title>
<sec id="FPar1">
<title>Outpatient/inpatient visits</title>
<p id="Par27">All evaluated studies show that most TSC patients have a high rate of outpatient physician contacts, regardless of the medical system [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] (see Table <xref ref-type="table" rid="Tab3">3</xref>). Rates of physician contact generally are much higher than in the general population, three times as high in TSC patients in the UK [<xref ref-type="bibr" rid="CR23">23</xref>]. However, in the UK, a high rate of adult general practitioner visits contrasted with an 88.5% rate of individuals who had never seen a neurologist and one-third of pediatric patients who had not seen a pediatrician during the last 3 years [<xref ref-type="bibr" rid="CR23">23</xref>]. Data from Germany [<xref ref-type="bibr" rid="CR116">116</xref>] revealed that one-half of people with TSC (51.5%) visited an epilepsy center less than once a year, and 46.6% scheduled at least two follow-up visits per year. In general, children were most frequently seen by neurologists, pediatricians, and ophthalmologists, adult patients most often visited neurologists, psychiatrists, and dermatologists, probably reflecting the changing clinical course of TSC throughout life [<xref ref-type="bibr" rid="CR23">23</xref>]. In Swedish individuals with TSC [<xref ref-type="bibr" rid="CR27">27</xref>], almost all (87.8%) of the study participants had experienced an outpatient visit with an International Classification of Disease 10th Edition (ICD-10) code identifying epilepsy.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Health care resource use in TSC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Measure</th><th>Country of study origin</th><th>Value</th></tr></thead><tbody><tr><td colspan="3">Outpatient visits</td></tr><tr><td colspan="3"> Overall contact with physician</td></tr><tr><td>  within the past year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>99% of children and 98% of adults</td></tr><tr><td>  within the past year for diagnosis “epilepsy”</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>87.8%</td></tr><tr><td>  per year (neurologist)</td><td>Germany [<xref ref-type="bibr" rid="CR116">116</xref>]</td><td>42.0%</td></tr><tr><td colspan="3"> Frequency of physician contact</td></tr><tr><td>  within the past year (overall)</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>22 (on average almost two times a month)</td></tr><tr><td>  per year (overall)</td><td><p>Canada [<xref ref-type="bibr" rid="CR104">104</xref>]</p><p>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</p></td><td><p>14 (mean, SD: 1.0), significantly more than the general population (8.3; SD: 0.3)</p><p>4.70 (mean, SD: 4.17); 1.65 (mean, SD: 1.95) for the ICD-10 code “epilepsy”</p></td></tr><tr><td>  per year (outpatient specialist)</td><td>Canada [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td>8.7 (mean, SD 0.6)</td></tr><tr><td>  within the past 3 years (general practitioner)</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>60.8 (on average)</td></tr><tr><td>  within the past 3 years (outpatient specialist)</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>15.3 (on average)</td></tr><tr><td colspan="3">Inpatient visits</td></tr><tr><td colspan="3"> Overall rate of hospital admission</td></tr><tr><td>  within 1 year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>37%</td></tr><tr><td>  within 5 years</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>85%</td></tr><tr><td>  within 16 years</td><td>Canada [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td>84.8%</td></tr><tr><td>  within 5 years (intensive care unit admission)</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>22.1%</td></tr><tr><td colspan="3"> Frequency of hospital admission</td></tr><tr><td>  within one year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>0.5 (0.28 for neurological complications)</td></tr><tr><td>  within the past year (emergency room)</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>2 (on average)</td></tr><tr><td>  within the past year (excluding emergency room)</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>2 (on average)</td></tr><tr><td>  within the past 3 years</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>3.4 (on average; two [<xref ref-type="bibr" rid="CR23">23</xref>] to three [<xref ref-type="bibr" rid="CR111">111</xref>] times the general population)</td></tr><tr><td>  per 10 person-years</td><td>Canada [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td><p>2.5; SD: 3.2 (vs. 1.3 admissions; SD: 1.5 in the general population)</p><p>5.8; SD: 2.1 for TSC-LAM</p></td></tr><tr><td> Annual length of stay</td><td><p>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</p><p>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</p></td><td><p>5.4 days (mean, SD: 3.0)</p><p>3.25 days (mean, SD: 5.61) overall, 2.06 days (mean, SD 4.50) due to epilepsy</p></td></tr><tr><td> Average length of stay</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>6.2 days (on average; 6 days for admissions due to neurological complications)</td></tr><tr><td colspan="3">Diagnostic procedures</td></tr><tr><td> Number of patients with three or more procedures/year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>90.5%</td></tr><tr><td> Average number of procedures/year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>9</td></tr><tr><td colspan="3"> Patients with (at least one)</td></tr><tr><td>  EEG/year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>93.7%</td></tr><tr><td>  EEG/year</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td><p>46.9% of children</p><p>10.9% of adults.</p></td></tr><tr><td>  Long-term EEG/year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>64%</td></tr><tr><td>  MRI/year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>90.5%</td></tr><tr><td>  MRI/year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>66%</td></tr><tr><td>  MRI/year</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td><p>58.0% of children</p><p>21.1% of adults</p></td></tr><tr><td>  MRI/ last 3 years</td><td>Germany [<xref ref-type="bibr" rid="CR116">116</xref>]</td><td>78.6%</td></tr><tr><td>  Regular MRI in SEGA</td><td>France [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td>15%</td></tr><tr><td>  CT/year</td><td>USA [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>55.8%</td></tr><tr><td>  Blood test/year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>57%</td></tr><tr><td>  Ultrasound/year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>45%</td></tr><tr><td>  Ophthalmologic evaluation/year</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>40%</td></tr><tr><td>  Renal screening/ last 3 years</td><td>Germany [<xref ref-type="bibr" rid="CR116">116</xref>]</td><td>56.1% (specific screening modality not reported)</td></tr><tr><td>  Renal screening</td><td>France [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td>78, 40% regularly every 2 years</td></tr><tr><td>  Psychiatric evaluation in those with TAND</td><td>France [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td>13% (psychological or psychiatric follow-up)</td></tr><tr><td colspan="3">ASD and other medication use</td></tr><tr><td> mTOR inhibitor</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>15.3% (for any indication; not differentiated)</td></tr><tr><td colspan="3"> ASD use</td></tr><tr><td>  in individuals with epilepsy</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>97.9% (378/386)</td></tr><tr><td>  in children</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>69%</td></tr><tr><td>  in adults</td><td><p>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</p><p>UK [<xref ref-type="bibr" rid="CR23">23</xref>]</p></td><td><p>25%</p><p>88%</p></td></tr><tr><td>  Most common ASD</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td><p>valproate (174/386; 45.1%)</p><p>lamotrigine (167/386; 43.3%)</p><p>carbamazepine (145/386; 37.6%)</p><p>levetiracetam (141/386; 36.5%)</p></td></tr><tr><td>  Most common ASD</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]</td><td><p>Carbamazepine (48.8%)</p><p>Valproate (48.8%)</p><p>Vigabatrine (43.2% children vs. 24.4% adults)</p></td></tr><tr><td colspan="3"> Anxiolytic medication use</td></tr><tr><td>  overall</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>72.5% (includes the potential use of benzodiazepines as ASD; not differentiated)</td></tr><tr><td>  in children</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>21%</td></tr><tr><td>  in adults</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>37%</td></tr><tr><td colspan="3"> Antipsychotic medication use</td></tr><tr><td>  overall</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>16.6%</td></tr><tr><td>  Most common antipsychotic medication</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>risperidone (11.4%)</td></tr><tr><td colspan="3"> Anxiolytic medication use</td></tr><tr><td>  in children/ past 3 years</td><td>UK [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]</td><td>20.3–37% (includes hypnotic medication)</td></tr><tr><td>  in adults/ past 3 years</td><td>UK [<xref ref-type="bibr" rid="CR110">110</xref>]</td><td>33.3% (includes hypnotic medication)</td></tr><tr><td> Antidepressants in children</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>15%</td></tr><tr><td colspan="3"> Psychoanaleptic medication use</td></tr><tr><td>  overall</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>23.6%</td></tr><tr><td>  in children</td><td>USA [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>19.9%</td></tr><tr><td>  in adults</td><td>USA [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td>20%</td></tr><tr><td>  Most common</td><td>Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>methylphenidate (7.3%)</td></tr><tr><td colspan="3">Surgical procedures</td></tr><tr><td> Epilepsy surgery</td><td>USA/Belgium [<xref ref-type="bibr" rid="CR120">120</xref>], Germany [<xref ref-type="bibr" rid="CR126">126</xref>], Sweden [<xref ref-type="bibr" rid="CR27">27</xref>], multinational [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td>6.5–25.3%</td></tr><tr><td colspan="3">Surgery for SEGA</td></tr><tr><td> Brain surgery (no differentiation)</td><td>USA, UK [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]</td><td>7.2–8.4%</td></tr><tr><td> Craniotomy</td><td>USA [<xref ref-type="bibr" rid="CR112">112</xref>]</td><td>5%</td></tr><tr><td> Cerebral shunt</td><td>USA [<xref ref-type="bibr" rid="CR112">112</xref>]</td><td>3.5%</td></tr><tr><td>Vagal nerve stimulator implantation</td><td>Multinational [<xref ref-type="bibr" rid="CR26">26</xref>], Sweden [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>3.8–6.0%</td></tr></tbody></table><table-wrap-foot><p><italic>ASD</italic> antiseizure drug, <italic>EEG</italic> electroencephalogram, <italic>CT</italic> computed tomography, <italic>ICD-10</italic> International Classification of Diseases - 10th Revision, <italic>MRI</italic> magnetic resonance imaging, <italic>SD</italic> standard deviation, <italic>SEGA</italic> subependymal giant cell astrocytoma, <italic>TAND</italic> TSC-associated neuropsychiatric disorders, <italic>TSC</italic> tuberous sclerosis complex, <italic>TSC-LAM</italic> tuberous sclerosis complex with lymphangioleiomyomatosis</p></table-wrap-foot></table-wrap></p>
<p id="Par28">Individuals with TSC-associated epilepsy living in the UK had on average 3.4 inpatient admissions in three years, which is almost three times the rate of the general population [<xref ref-type="bibr" rid="CR23">23</xref>] with similar to slightly lower numbers reported from the general TSC population in the US [<xref ref-type="bibr" rid="CR56">56</xref>] and Canada [<xref ref-type="bibr" rid="CR104">104</xref>]. Mean annual length of stay (LOS) was 5.4 days (SD: 3.0) in the US study [<xref ref-type="bibr" rid="CR56">56</xref>], longer than in a Swedish study (mean 3.25 days; SD: 5.61) [<xref ref-type="bibr" rid="CR27">27</xref>]. More than half (59.8%) of individuals had an inpatient visit with an ICD-10 code identifying epilepsy in the Swedish study [<xref ref-type="bibr" rid="CR27">27</xref>]. Another study from the US reported about half of hospitalizations per year per patient were due to neurological complications. In a US study, persons with TSC-associated neurological manifestations required significantly more hospitalizations than did those without. Children with TSC and developmental impairment had significantly more ICU stays as compared with cognitively unimpaired children [<xref ref-type="bibr" rid="CR24">24</xref>]. Individuals with TSC and epileptic spasms or refractory epilepsy and young patients had the highest mean health care utilization in a Swedish study [<xref ref-type="bibr" rid="CR27">27</xref>]. This pattern was true for all evaluated categories of health care utilization [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
</sec>
<sec id="FPar2">
<title>Diagnostic procedures</title>
<p id="Par29">Individuals with TSC receive a high number of diagnostic procedures each year. Consistently, the most commonly performed procedures in individuals with TSC are EEG (10.9–93.7%/year), MRI for any indication (22.1–90.5%), CT for any indication (55.8%), blood tests (57%) and ultrasound (45%) [<xref ref-type="bibr" rid="CR56">56</xref>]. However, the frequency varies between different medical systems. A study from the US [<xref ref-type="bibr" rid="CR24">24</xref>] found that, within 5 years, 90.5% underwent three or more diagnostic procedures. The frequency of diagnostic test in a UK study [<xref ref-type="bibr" rid="CR23">23</xref>] was much lower (on average 1.1/3 years), which was still 5 times more than in the general population. In a Dutch study, individuals with TSC and CKD stage III had more scans, nonsurgical procedures, and specialist visits than did those with lower stages of CKD [<xref ref-type="bibr" rid="CR35">35</xref>]. A multicenter survey from Germany [<xref ref-type="bibr" rid="CR116">116</xref>] reported that presurgical diagnostics were performed in 27% of patients. Of note, in 34% of individuals with TSC and epilepsy in the UK study, no diagnostic test had ever been performed, while 24.9% had only ever had one test (see Table <xref ref-type="table" rid="Tab3">3</xref>). Several studies show an incomplete observation of the TSC Surveillance and Management Recommendations [<xref ref-type="bibr" rid="CR127">127</xref>] regarding diagnostic renal screening. In a German study, 56.1% of individuals had had renal screening (modality not reported) in the last 3 years [<xref ref-type="bibr" rid="CR116">116</xref>] and a psychiatric evaluation had been performed in only 13% of individuals with TAND in a French study [<xref ref-type="bibr" rid="CR53">53</xref>]. Regular neurologic follow-up (62%), regular SEGA brain imaging (15%) and nephrologic screening (40%) also was not regularly applied in all patients [<xref ref-type="bibr" rid="CR53">53</xref>]. In an Australian cohort, adults were significantly less likely to follow surveillance guidelines as compared with children (36% vs. 89%) [<xref ref-type="bibr" rid="CR128">128</xref>].</p>
</sec>
<sec id="FPar3">
<title>Anti-seizure drugs (ASDs) and other medication use</title>
<p id="Par30">Data from several countries show that ASD are the most common drug class used in individuals with TSC (69–97.9%), followed by anxiolytic medication (21–72.5%), psychoanaleptics (19.9–23.6%) and antipsychotics (16.6–37%%) [<xref ref-type="bibr" rid="CR27">27</xref>]. Inhibitors of mTOR were used in 15.3% in one study, without differentiation of application or indication [<xref ref-type="bibr" rid="CR27">27</xref>]. Anxiolytic therapy may be overstated, as benzodiazepines are also used as ASD and several studies do not precisely differentiate between related drug classes or indications [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. In TOSCA, 98.1% of patients with focal seizures received ASD treatment, most commonly with GABAergic anticonvulsants (66%) [<xref ref-type="bibr" rid="CR26">26</xref>]. In the Swedish national insurance database [<xref ref-type="bibr" rid="CR27">27</xref>] the most common ASD were valproate (45.1%), lamotrigine (43.3%), carbamazepine (37.6%), and levetiracetam (36.5%). Vigabatrine is used significantly more often by children (43.2%) than adults (24.4%) as reported from UK data [<xref ref-type="bibr" rid="CR23">23</xref>]. Several studies showed that individuals with TSC require between four and eight times more prescriptions than the general population [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. In a UK study, hypnotics or antipsychotic drugs (not differentiated) were prescribed twice as often in individuals with TSC than in the general population. In particular, the difference was sevenfold in children with TSC as compared with in the general population [<xref ref-type="bibr" rid="CR110">110</xref>]. However, in a French study in which 80% had intellectual disabilities and 70% had psychiatric disorders, only 20% received pharmacotherapy [<xref ref-type="bibr" rid="CR53">53</xref>]. Overall medication use in individuals with TSC and renal manifestation was found to be higher in CKD stage III than in lower stages [<xref ref-type="bibr" rid="CR35">35</xref>]. The ketogenic diet was used by 1.6 to 4.7% of individuals [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p>
</sec>
<sec id="FPar4">
<title>Other procedures (surgery, etc.)</title>
<p id="Par31">A study examining [<xref ref-type="bibr" rid="CR120">120</xref>] US and Belgian TSC patients reported a rate of epilepsy surgery of 25.3%, a German study of 9% [<xref ref-type="bibr" rid="CR126">126</xref>] while national insurance data offered a rate of 6.5% for Sweden [<xref ref-type="bibr" rid="CR27">27</xref>], similar to the 6.9% of epilepsy patients in TOSCA [<xref ref-type="bibr" rid="CR26">26</xref>]. Brain surgery without further differentiation regarding indication was reported in 8.4% in a US study [<xref ref-type="bibr" rid="CR24">24</xref>] and 7.2% in a UK study [<xref ref-type="bibr" rid="CR23">23</xref>]. In a US database analysis of 5655 individuals with TSC, 5% had received a craniotomy and 3.5% had a cerebral shunt. The median LOS for these procedures was 3 days [interquartile range (IQR): 2–6 days] [<xref ref-type="bibr" rid="CR112">112</xref>]. Additionally, in a US study [<xref ref-type="bibr" rid="CR24">24</xref>], brain electrodes were implanted in 6.3% of patients, but the rationale (diagnostic vs. therapeutic) was not provided in detail. Reported rates of VNS implantation are between 3.8% in TOSCA and 6.0% [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In a small study, nine of 11 patients (82%) had at least a 67% reduction in seizure burden [<xref ref-type="bibr" rid="CR129">129</xref>]. Seizure freedom after epilepsy surgery was reported as 57% in a German study [<xref ref-type="bibr" rid="CR116">116</xref>], in line with smaller studies performed on children [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR130">130</xref>], and a systematic review (Engel class 1 achieved in 57% of TSC patients) [<xref ref-type="bibr" rid="CR131">131</xref>]. Intellectual ability was significantly better in those with Engel class 1 outcome. Another study on outcomes of pediatric epilepsy surgery found at least a moderate improvement was achieved in 46 to 85% of patients. There was a significant correlation between quality of life measures and a favorable Engel outcome class [<xref ref-type="bibr" rid="CR132">132</xref>]. For a review on epilepsy surgery in TSC, see Jansen et al. and Evans et al. [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR133">133</xref>].</p>
<p id="Par32">Regarding kidney interventions, individuals with TSC-associated renal impairment and CKD stage III underwent more surgeries than did those in lower stages [<xref ref-type="bibr" rid="CR35">35</xref>]. Eijkemans et al. [<xref ref-type="bibr" rid="CR86">86</xref>] noted that individuals in the same Dutch cohort with higher stages of AML required more renal embolization. Renal transplantation does rarely occur in TSC and generally has favorable results. The BOI of this surgical intervention has not been evaluated [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>].</p>
</sec>
<sec id="FPar5">
<title>Other therapies (physical, educational, etc.)</title>
<p id="Par33">Only very few studies have looked at therapies in TSC that are not administered by physicians. In a US study [<xref ref-type="bibr" rid="CR24">24</xref>], almost half of patients (43.2%) required rehabilitation services, including most commonly occupational and speech-language therapy (each 34.7%). Physical therapy was performed in 31.6% and special education services in 14.7% of patients, respectively. Developmentally impaired children and individuals with neurological manifestation in general required more rehabilitative effort than did those without. The low number of special education services reported in this study is probably due to incomplete assessment in some age groups [<xref ref-type="bibr" rid="CR24">24</xref>]. In a French cohort with a prevalence of psychiatric disorders of 70%, only 13% had a psychological or psychiatric follow-up [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
<sec id="FPar6">
<title>TSC centers</title>
<p id="Par34">The share of patients treated at TSC centers as opposed to non-integrated care was reported by 10 studies. In those not recruiting patients from a TSC center, the rate of patients treated at a TSC center was between 27.9 and 51.7%. Data from the US suggested that almost half of all patients received their care at TSC centers [<xref ref-type="bibr" rid="CR56">56</xref>]. A German multicenter survey [<xref ref-type="bibr" rid="CR116">116</xref>] also showed that medical care involved a TSC center in 27.9% of cases, and 36.6% of patients reported the visit of an urologist or nephrologist in addition to the epilepsy center consultation.</p>
</sec>
</sec>
<sec id="Sec16">
<title>Direct costs</title>
<p id="Par35">A UK study [<xref ref-type="bibr" rid="CR110">110</xref>] estimated that the total costs incurred by individuals with TSC were 2.7 times higher than such in the general UK population. An individual with TSC reportedly incurs a mean total cost of GBP 12,681 (PPP-$ 17,629) over a three-year period as compared with GBP 4777 (PPP-$ 6641) per general population patient. On average, the highest per-patient costs were incurred by (overall rare) respiratory manifestations (GBP 40,312, PPP-$ 56,040). Structural brain manifestations led to the highest three-year cost (GBP 22,139, PPP-$ 30,777), followed by renal and urinary tract manifestations (GBP 15,162, PPP-$ 21,078) and nervous system manifestations (GBP 14,355, PPP-$ 19,956). Manifestations in the renal and nervous system were each found to significantly impact costs. Also, the number of organ systems involved was found to be a significant cost driver, with statistical significance persisting as the number of manifestations increased. However, age and sex were not found to significantly impact costs [<xref ref-type="bibr" rid="CR110">110</xref>].</p>
<p id="Par36">In a subgroup analysis, the same UK group [<xref ref-type="bibr" rid="CR111">111</xref>] estimated the direct costs of TSC patients with renal manifestations. The total average cost for a TSC patient with renal manifestations was almost three times higher than that in the general population (GBP 15,162, PPP-$ 21,078 vs. GBP 5672, PPP-$ 7885) in 2014. All cost aspects were substantially higher in individuals with TSC-associated renal manifestations. Among TSC patients, a more than twofold increase in direct costs was seen for GP visits and inpatient hospitalizations, while more than three times the typical cost was accrued for outpatient visits and primary care drugs (see Table <xref ref-type="table" rid="Tab4">4</xref>). At the same time, no kidney-related procedures were performed in 70.9% of individuals with TSC, while more than one-quarter did not undergo the recommended amount of renal screening procedures. A Dutch study [<xref ref-type="bibr" rid="CR35">35</xref>] reported that higher health-care resource use (HRCU) is associated with male gender, CKD greater than stage I, AML size of 3.5 cm or larger, embolization, and the presence of moderate or severe LAM. Higher costs in CKD stage V were consequently induced by dialysis. The overall costs were EUR 1275 (PPP-$ 1715) for CKD stage I, EUR 3547 (PPP-$ 4770) for stage IV, and EUR 31,916 (PPP-$ 42,921) for stage V (defined as any patient requiring dialysis), respectively (all costs originally represented in 2012 EUR). The single biggest cost in CKD stages I and II was surgery. Conversely, for stages III and IV, it was medication and, for stage V, costs were primarily driven by dialysis. Patients aged 60 years or older had lower costs as compared with patients aged younger than 20 years, maybe owing to less frequent testing. In a US study based on commercial and governmental claims data [<xref ref-type="bibr" rid="CR114">114</xref>] adult and pediatric TSC patients with AML utilized more resources than did the general population. Direct health care costs (in 2013 USD) in commercial claims were between USD 29,240 (PPP-$ 31,605) and USD 48,499 (PPP-$ 52,422) for TSC patients, or 14 to 22 times higher than that in the general population.</p>
<p id="Par37">TSC patients with LAM also have significantly higher health care costs. In a Canadian study, health care costs in the TSC population (1004 individuals) were almost twice as high as in the general population. In addition, 38 patients with LAM had even higher health care costs [<xref ref-type="bibr" rid="CR104">104</xref>] (see Table <xref ref-type="table" rid="Tab4">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Direct costs in TSC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>N patients total</th><th>Group</th><th>Costing year</th><th>Original cost figure given</th><th>Cost/year/patient (calculated)</th><th>Cost in 2018 PPP-$</th><th>Significant cost drivers (in regression analysis)</th><th>Out-of-pocket spending</th><th>Cost per admission</th><th>Further measures</th></tr></thead><tbody><tr><td>Shepherd et al. 2017 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>286</td><td>TSC and epilepsy</td><td>2014</td><td>GBP 14,335 / 3y</td><td>GBP 4778</td><td>6643</td><td>number of organ systems involved; combination of kidney and urinary/dermatological manifestations</td><td>n. r.</td><td>n. r.</td><td></td></tr><tr><td>Vekeman et al. 2015 – CKD Stage I [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td rowspan="2">369</td><td rowspan="2">TSC and renal manifestations</td><td>2012</td><td>EUR 1275</td><td>EUR 1275</td><td>1715</td><td rowspan="2">CKD stage V vs. CKD stage I; AML size &gt; = 3,5 cm; comorbid moderate or severe LAM</td><td rowspan="2">n.r.</td><td rowspan="2">n. r.</td><td rowspan="2"></td></tr><tr><td>Vekeman et al. 2015 – CKD Stage V [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td>2012</td><td>EUR 30,641</td><td>EUR 30,641</td><td>41,207</td></tr><tr><td>Kingswood et al. 2016a [<xref ref-type="bibr" rid="CR110">110</xref>]</td><td>278<sup>b</sup></td><td>All TSC</td><td>2014</td><td>GBP 12,681 /3y</td><td>GBP 4227</td><td>5876</td><td>number of organ systems involved; kidney and urinary tract manifestations, nervous system manifestations; <italic>pairwise:</italic> circulatory/kidney and urinary tract, nervous system/psychiatric, dermatological/kidney &amp; urinary tract manifestations</td><td>n. r.</td><td>n. r.</td><td><p><italic>GP visits</italic> (GBP 3433, PPP-$ 4772 vs. GBP 1283, PPP-$ 1784)</p><p><italic>inpatient hospitalizations</italic> (GBP 7050, PPP-$ 9801 vs. GBP 3298, PPP-$ 4585)</p><p><italic>outpatient visits</italic> (GBP 2071, PPP-$ 2879 vs. GBP 613, PPP-$ 852)</p><p><italic>primary care drugs</italic> (GBP 2607, PPP-$ 3624 vs. GBP 479, PPP-$ 666)</p></td></tr><tr><td>Kingswood et al. 2016b [<xref ref-type="bibr" rid="CR111">111</xref>]</td><td>79<sup>b</sup></td><td>TSC and renal manifestations</td><td>2014</td><td>GBP 15,162 / 3y</td><td>GBP 5054</td><td>7026</td><td>number of primary TSC manifestations; nervous system manifestations; <italic>pairwise:</italic> combination of dermatology/psychiatric manifestations</td><td>n. r.</td><td>n. r.</td><td></td></tr><tr><td>Skalicky et al. 2018 [<xref ref-type="bibr" rid="CR119">119</xref>]</td><td>609<sup>a</sup></td><td>all TSC</td><td>2018</td><td><p>Tests/procedures: USD 5499-20,403</p><p>Hospital expenses: USD 1263-5533</p><p>Doctor’s visits: USD 1646-4462</p><p>ER visits: USD 702–2671</p></td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td><p>For tests and/or procedures: USD 5499-20,403</p><p>Hospital expenses: USD 1263-5533</p><p>Doctor’s visits: USD 1646-4462</p><p>ER visits: USD 702–2671</p></td><td>n. r.</td><td></td></tr><tr><td>Skalicky et al. 2015 [<xref ref-type="bibr" rid="CR106">106</xref>]</td><td>116<sup>a</sup></td><td>TSC and SEGA</td><td>2015</td><td>USD 80–129</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>median monthly: USD 80–129 (about 50% of patients)</td><td>n.r.</td><td></td></tr><tr><td>Song X. et al. 2017 [<xref ref-type="bibr" rid="CR114">114</xref>]</td><td>743</td><td>TSC and AML</td><td>2013</td><td>USD 29,240-48,499</td><td>USD 29,240 to 48,499</td><td>31,605 to 52,422</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td></td></tr><tr><td>Wilson et al. 2016 [<xref ref-type="bibr" rid="CR112">112</xref>]</td><td>5655 (admissions)</td><td>all TSC</td><td>n. r.</td><td>USD 14,807 (IQR 7319-31,180)</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>USD 14,807 (IQR 7319-31,180)</td><td></td></tr><tr><td rowspan="2">Sun et al. 2015 [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td rowspan="2">47</td><td rowspan="2">TSC and SEGA surgery</td><td rowspan="2">2010</td><td rowspan="2"><p>USD 8543.1 (SD 11,187.6) for presurgical year</p><p>USD 85,397 (SD 56,258.9) for postsurgical year</p></td><td rowspan="2">USD 8543 to 85,397</td><td rowspan="2">9805 to 98,008</td><td rowspan="2">n. r.</td><td rowspan="2">n. r.</td><td rowspan="2">n. r.</td><td><p>Presurgical year: <italic>inpatient</italic> USD 3770, PPP-$ 4327</p><p><italic>outpatient treatments</italic> USD 3473, PPP-$ 3986 <italic>Medications</italic> USD 1300, PPP-$ 1492</p></td></tr><tr><td><p>postsurgical year</p><p><italic>surgery</italic> USD 71,562, PPP-$ 82,130</p><p><italic>Outpatient costs</italic> USD 11,497 PPP-$ 13,195 <italic>medication costs</italic> USD 2338, PPP-$ 2683</p><p>(costs 1.6 to 4.3 times higher than in the presurgical year [inpatient: 4.3:1, outpatient: 2.5:1, medication: 1.6:1, and total: 3.1:1])</p></td></tr><tr><td>Kristof et al. 2015 [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td><p>1004 (TSC)</p><p>29 (LAM)</p></td><td>TSC and/or LAM</td><td>2011</td><td><p>TSC: CAD 513 (SD 5.83)</p><p>LAM: CAD 1434 (SD 10.14)</p><p>TSC-LAM: CAD 1718 (SD 10.53)</p><p>General population control: CAD 281 (SD 4.37)</p></td><td>CAD 513 to 1718</td><td>424 to 1421</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>, <sup>b</sup> denotes patients originating from same cohort; <italic>AML</italic> Angiomyolipoma, <italic>CAD Canadian dollar, CCHMC</italic>
<italic>Cincinnati Children’s Hospital Medical Center, CKD Chronic kidney disease, ER</italic> Emergency room, <italic>GBP Great Britain pound, HDI-SF</italic> Hamilton depression inventory short form, <italic>ICF</italic> International classification of functioning, disability, and health, <italic>IQR</italic> Interquartile range, <italic>LAM</italic> Lymphangioleiomyomatosis, <italic>n. r.</italic> Not reported, <italic>PedsQL Pediatric quality of life inventory, PPPY</italic> Cost per person per year, <italic>PPP-$</italic> International Dollar purchasing power parities, <italic>SEGA</italic> Subependymal giant astrocytoma, <italic>SF12</italic> Short form health survey 12-item, version 2, <italic>TSC</italic> Tuberous sclerosis complex, <italic>USD United States dollar, WPAI CIQ-SHP</italic> Work Productivity and Activity Impairment plus Classroom Impairment Questions: Special Health Problem (WPAI CIQ-SHP), version 2 questionnaire; for data sources please refer to Table <xref ref-type="table" rid="Tab2">2</xref></p></table-wrap-foot></table-wrap></p>
<p id="Par38">Sun et al. [<xref ref-type="bibr" rid="CR107">107</xref>] evaluated costs in patients undergoing SEGA resective surgery. In the postsurgical year, patient costs were three-fold higher than in the presurgical year, with a high inpatient proportion being attributed to surgery. Long-term costs were not assessed by the study. Another US study [<xref ref-type="bibr" rid="CR112">112</xref>] showed that median hospital stay charges for TSC patients with craniotomy were USD 65,885 (IQR: USD 39,195–120,180). This was more than four times the financial amount charged of those not receiving craniotomy. Long-term follow-up costs were likewise not assessed in the study.</p>
<p id="Par39">Skalicky et al. [<xref ref-type="bibr" rid="CR119">119</xref>] analyzed economic burden in a cohort described previously [<xref ref-type="bibr" rid="CR56">56</xref>]. Adult patients had significantly higher out-of-pocket direct costs than did pediatric patients. In this study, more than two-thirds of patients worked for pay, but the type (primary vs. subsidized labor market) was not stated by the authors. TSC patients had substantial yearly out-of-pocket costs (median of USD 1750 for pediatric and median of USD 3270 for adult patients, respectively) for both outpatient and hospital care in a US cohort [<xref ref-type="bibr" rid="CR106">106</xref>]. In a study on BOI of facial angiofibromas in a US population, the cost of medication and lack of a suitable pharmacy were seen as biggest hurdles in receiving topical rapamycin therapy [<xref ref-type="bibr" rid="CR108">108</xref>], but average costs were not given.</p>
</sec>
<sec id="Sec17">
<title>Projected costs</title>
<p id="Par40">Fallah et al. [<xref ref-type="bibr" rid="CR109">109</xref>] estimated the theoretical cost-effectiveness of four different therapy strategies in pediatric TSC patients with drug-refractory epilepsy, specifically epilepsy surgery, VNS, ketogenic diet, and carbamazepine as an additional third ASD. The cost-effectiveness was modeled based on adjusted historic costs and data from an open cost-effectiveness registry. In pediatric patients with drug refractoriness to two ASDs and the fundamental possibility of epilepsy surgery, the addition of a third ASD was the most cost-effective solution (USD 6568 for 4.14 QALY). In a further estimate, patients with three ASDs who did not achieve seizure freedom could most cost-effectively be helped by epilepsy surgery (USD 77,675 for 4.38 QALY), followed by the addition of a fourth ASD (USD 50,862 for 4.11 QALY) and ketogenic diet treatment (USD 16,228 for 3.60 QALY). Which of those strategies was best depended upon health-care system resources. In resource-rich countries, epilepsy surgery was deemed as the most effective treatment and ketogenic diet in resource-limited environments. Mechanistic target of rapamycin (mTOR) inhibitor treatment for epilepsy alone was not a cost-effective treatment strategy based on the costs induced by the mTOR therapy in the historic reports, given at USD 134,436/year (range USD 142,737–160,462) [<xref ref-type="bibr" rid="CR109">109</xref>].</p>
</sec>
<sec id="Sec18">
<title>Individual and caregiver burden of illness and quality of life</title>
<p id="Par41">In comparison with the studies focusing on health care resource use, there are fewer studies focusing on individual BOI in TSC. In a UK study, impaired QoL in psychosocial and physical domains was apparent in all adults and children, regardless of the presence of epilepsy or intellectual disability [<xref ref-type="bibr" rid="CR121">121</xref>] (as measured by the Pediatric Quality of Life Inventory [PedsQL] and the Short Form (36 items) Health Survey 36 [SF-36]). Nevertheless, quality of life is lower in those with TSC and epilepsy than in those with TSC with only renal AML, primarily attributable to reduced cognitive functioning [<xref ref-type="bibr" rid="CR123">123</xref>]. Quality of life and daily functioning worsens with increasing seizure frequency or severity [<xref ref-type="bibr" rid="CR122">122</xref>], and pharmacoresistant epilepsy significantly reduces QoL [<xref ref-type="bibr" rid="CR121">121</xref>]. Older age and reduced daily functioning also negatively affect quality of life (as measured by the Health Utility Index version 3 [HUI-3] questionnaire) [<xref ref-type="bibr" rid="CR123">123</xref>]. In a US web-based survey study [<xref ref-type="bibr" rid="CR105">105</xref>], adults with TSC named skin lesions (15%), sleep problems (10%), and kidney complications (9%) as the “most bothersome” aspects of TSC. Crall et al. [<xref ref-type="bibr" rid="CR108">108</xref>] showed that individuals with TSC experienced no negative impact of facial angiofibroma on their QoL, as measured by dermatological QoL scales. However, patients who received therapy for their AF reported better dermatological QoL than did those who did not. Quality of life in children with TSC is worse than in diabetes, cancer and inflammatory bowel disease, when evaluating the PedsQL [<xref ref-type="bibr" rid="CR121">121</xref>]. Individuals with TSC patients had a better QoL than Alzheimer’s disease sufferers but worse than rheumatoid arthritis sufferers and the general healthy population in the HUI-3 [<xref ref-type="bibr" rid="CR123">123</xref>].</p>
<p id="Par42">One study reported on QoL measures as secondary treatment outcome of everolimus for children with pharmacoresistant epilepsy. After 12 weeks of treatment, the overall QoL was significantly better, driven by many domains (primarily by attention, behavior, other cognitive, social interaction, stigma, physical restrictions and social activity), as measured by the QOLCE [<xref ref-type="bibr" rid="CR103">103</xref>]. In a study on resective and disconnective surgeries in pharmacoresistant epilepsy, the QoL showed significant improvement in all patients, especially patients with low preoperative intelligence quotient (IQ) and postoperative seizure freedom or disconnection of the corpus callosum, as measured by neuropsychological evaluation and the QOLIE-31 [<xref ref-type="bibr" rid="CR101">101</xref>]. Of note, antiseizure medication and mTOR therapy can have adverse reactions, most commonly dizziness and nausea in ASD. Everolimus therapy leads to stomatitis in a substantative share of patients (43.2%, according to final results from the EXIST-1 [<xref ref-type="bibr" rid="CR134">134</xref>], but rarely grade 3 or 4) and can increase the risk of pneumonia. The effects on BOI by these adverse reactions have not been studied explicitly.</p>
<p id="Par43">A subgroup-analysis [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR105">105</xref>] examined the physical and mental health burdens on caregivers providing assistance to individuals with TSC. Caregivers declared seizures (32%), cognitive impairments (25%), and skin lesions (15%) as the “most bothersome” concerns. Overall, caregivers of people with TSC had significantly lower QoL scores in both physical and mental domains and had more depressive symptoms than the general healthy US population [<xref ref-type="bibr" rid="CR105">105</xref>]. Caregiver QoL is negatively affected by facial angiofibroma of the patient [<xref ref-type="bibr" rid="CR108">108</xref>]. Behavioral problems, persisting seizures, and psychiatric comorbidities significantly increase parental stress [<xref ref-type="bibr" rid="CR117">117</xref>]. In a qualitative study [<xref ref-type="bibr" rid="CR115">115</xref>] in 16 individuals with TSC and 12 parents, the main concerns were mental and physical health, social participation, self-management skills, family planning, and the side effects of medications. Patients wished for multidisciplinary care that focused on the wellbeing of whole patient, including their family. At the same time, caregivers often feel overwhelmed and feel a lack of psychosocial support and orientation, as seen in a qualitative Italian study [<xref ref-type="bibr" rid="CR102">102</xref>]. This study highlighted that many caregivers find support in patient organizations rather than in their extended personal network [<xref ref-type="bibr" rid="CR102">102</xref>]. Transition from pediatric to adult health care frequently exacerbates the BOI in TSC patients due to changing health care providers and a loss of integrated care. A French study evaluated patient experiences during transition [<xref ref-type="bibr" rid="CR53">53</xref>]. In comparison, pediatric care was more regular and multidisciplinary than adult care. Epilepsy followed by renal issues had the best transition (best rate of follow-up). For psychiatric and behavioural disorders, transition was worse. Notably, only half of patients with a normal intellectual development had clear knowledge about their disorder and the need for a regular monitoring. The most stressful part of transition was the change of care structure and/or caregivers. Of note, only 10 % of individuals in the study rated their quality of life as good or excellent while more than half rated it as mediocre or bad (18%) [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
<p id="Par44">A US study [<xref ref-type="bibr" rid="CR105">105</xref>] reported that caregivers and TSC patients both missed about one-tenth of work time due to the disorder (11 and 15%, respectively). Adults with TSC, however, reported less overall work productivity and felt more work time was impaired by the disorder. However, none of the studies provided indirect cost estimates. In the French study, a third of patients had a stable income, but in 65% salary was below the national minimum wage [<xref ref-type="bibr" rid="CR53">53</xref>]. In a multinational study, only 17.7% reported working at least part-time (sector not reported) [<xref ref-type="bibr" rid="CR122">122</xref>].</p>
</sec>
<sec id="Sec19">
<title>Mortality</title>
<p id="Par45">Mortality is significantly higher in individuals with TSC than in the general population, please refer to Table <xref ref-type="table" rid="Tab5">5</xref> for details. A Dutch study demonstrated a fivefold higher mortality rate than that in the age- and gender-matched general population. In this study [<xref ref-type="bibr" rid="CR86">86</xref>], within 15.8 years, 29 of 351 individuals with TSC died (standardized mortality ratio: 4.8; 95% confidence interval: 3.4–6.9). A separate Swedish study [<xref ref-type="bibr" rid="CR27">27</xref>] found that 7.8% of individuals with TSC (<italic>n</italic> = 30) died during the study period (mean duration of observation: 8.82 years). In 50% (<italic>n</italic> = 15), death was directly related to TSC. A US study [<xref ref-type="bibr" rid="CR113">113</xref>] retrospectively identified 284 patients who attended a single center between 1981 and 2015. At the time of research, 16 individuals (5.6%) had died from complications of TSC, and the median age at death was 33 years. Shepherd and Gomez [<xref ref-type="bibr" rid="CR135">135</xref>] found in a US cohort that 48 of 355 individuals (13.5%) with TSC died. In addition, mortality in those with intellectual disabilities exceeds the mortality in those without [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. In one study, LAM shortened the life expectancy by 7 years in a US collective of women with TSC (70.5 vs. 63 years) [<xref ref-type="bibr" rid="CR124">124</xref>].
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Studies reporting mortality in TSC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study / cause of death</th><th>Epilepsy</th><th>Kidney</th><th>Brain structural</th><th>LAM</th><th>Other pulmonal</th><th>Infection/sepsis</th><th>Cardio-vascular</th><th>Unknown</th><th>Not described</th><th>Undiscriminated tumor / cancer</th><th>Undiscriminated, but TSC-associated</th><th>Certainly not TSC</th><th>Multiple causes</th><th>N of deceased patients in study</th><th>N of patients in study</th><th>Mortality (%)</th><th>Start evaluation period</th><th>End evaluation period</th><th>Calculated duration of evaluation period</th><th>Actual evaluated period</th></tr></thead><tbody><tr><td>Welin et al. 2017 [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>3</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>5</td><td>15</td><td>7</td><td>–</td><td>–</td><td>–</td><td>30</td><td>386</td><td>7.8</td><td>2004</td><td>2014</td><td>10</td><td>8.8</td></tr><tr><td>Amin et al. 2017 [<xref ref-type="bibr" rid="CR113">113</xref>]</td><td>4</td><td>8</td><td>1</td><td>2</td><td></td><td>–</td><td>–</td><td>–</td><td>–</td><td>1</td><td>–</td><td>–</td><td>–</td><td>16</td><td>284</td><td>5.6</td><td>1981</td><td>2015</td><td>34</td><td>8</td></tr><tr><td>Shepherd et al. 2017 [<xref ref-type="bibr" rid="CR135">135</xref>]</td><td>9</td><td>9</td><td>9</td><td>4</td><td></td><td>4</td><td>2</td><td></td><td></td><td>3</td><td>–</td><td>9</td><td></td><td>49</td><td>355</td><td>13.8</td><td>n. r.</td><td>n. r.</td><td>n. r.</td><td>n. r.</td></tr><tr><td>Eijkemans et al. 2015 [<xref ref-type="bibr" rid="CR86">86</xref>]</td><td>3</td><td>9</td><td></td><td></td><td></td><td></td><td></td><td>13</td><td></td><td>4</td><td>–</td><td>–</td><td>–</td><td>29</td><td>351</td><td>8.3</td><td>1990</td><td>2012</td><td>22</td><td>15.8</td></tr><tr><td>Kingswood et al. 2016 [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>16</td><td></td><td>–</td><td>–</td><td>–</td><td>16</td><td>334</td><td>4.8</td><td>1987</td><td>2013</td><td>26</td><td>17.4</td></tr><tr><td>Kristof et al. 2015 [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td>–</td><td>4</td><td>–</td><td>–</td><td>–</td><td>24</td><td>16</td><td></td><td>73</td><td>–</td><td>10</td><td>4</td><td></td><td>131</td><td>1004</td><td>13.0</td><td>1996</td><td>2011</td><td>15</td><td>n. r.</td></tr><tr><td>Zak et al. 2019 [<xref ref-type="bibr" rid="CR124">124</xref>]</td><td>9</td><td>1</td><td>1</td><td>6</td><td>2</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td></td><td>1</td><td>1</td><td>23</td><td>662</td><td>3.5</td><td>1998</td><td>2016</td><td>18</td><td>n. r.</td></tr><tr><td><bold>SUM</bold></td><td>28</td><td>31</td><td>11</td><td>12</td><td>2</td><td>29</td><td>18</td><td>19</td><td>104</td><td>15</td><td>10</td><td>14</td><td>1</td><td><bold>294</bold></td><td><bold>3376</bold></td><td><bold>Mean 8.7</bold></td><td>–</td><td>–</td><td><bold>Mean 20.8</bold></td><td><bold>Mean 12.5</bold></td></tr></tbody></table><table-wrap-foot><p><italic>LAM</italic> Lymphangioleiomyomatosis, <italic>n. r.</italic> Not reported, <italic>TSC</italic> Tuberous sclerosis complex; for data sources please refer to Table <xref ref-type="table" rid="Tab2">2</xref></p></table-wrap-foot></table-wrap></p>
<p id="Par46">When aggregating the data on all published mortality numbers in individuals with TSC, the most common causes of TSC-attributable deaths are epilepsy [especially status epilepticus and sudden unexpected death in epilepsy (SUDEP)], kidney complications, and complications from infections [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. Structural brain manifestations and LAM in women are other prevalent causes of TSC-associated death [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. While malignancies were commonly reported as a cause of death in the evaluated patients, further specifics were lacking. In general, the overall cancer rates are not elevated in TSC patients [<xref ref-type="bibr" rid="CR136">136</xref>].</p>
</sec>
</sec>
</sec>
<sec id="Sec20">
<title>Discussion</title>
<p id="Par47">The individual burden of illness in TSC is highly variable, resulting from the individual’s particular clinical manifestation in multiple organ systems over time [<xref ref-type="bibr" rid="CR137">137</xref>]. In general, TSC patients have a significantly increased BOI as compared with the general population. BOI is also higher than in many other chronic diseases [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. As evident by the results of this review, where 14 studies on quality of life used more than as many different questionnaires, standardized assessment of BOI in TSC is difficult. To facilitate BOI research in TSC, the use of evaluated and standardized questionnaires should be encouraged. While this is challenging in rare diseases, first steps in this direction have been made [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
<sec id="Sec21">
<title>Health care resource use</title>
<p id="Par48">Independent of specific health care systems, hospitalization rates of individuals with TSC are at least twice as high as those in the general population. Children with cognitive impairment and severe forms of epilepsy have an especially high hospitalization risk and are more likely to require ICU treatment. Outpatient physician visits are even more frequent relative to the general population, which is plausibly explained by the high number of specialist that individuals with TSC need to see. However, there is a dearth of information regarding frequency of non-physician outpatient therapies for TSC. While many individuals with TSC and caregivers lament the lack of support in the domains of psychological and physical functioning [<xref ref-type="bibr" rid="CR102">102</xref>], surprisingly little has been published regarding frequency of neuropsychological, occupational or physical therapy.</p>
<p id="Par49">Not surprisingly, individuals with TSC also require more medication than the general population and a high number of anxiolytic and antipsychotic medication was reported from several health systems [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. A closer evaluation of these therapies seems necessary especially considering the insufficient diagnosis of TAND in many patients. The use of mTOR inhibitors might prevent epileptogenesis and some of the late organ manifestations in patients with TSC and has the potential to decrease HRCU in the long-term [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>], but this has not yet been investigated.</p>
<p id="Par50">Individuals with TSC also undergo more diagnostic procedures than the general population. Nevertheless, studies have hinted at insufficient adherence to surveillance standards, especially in adults [<xref ref-type="bibr" rid="CR128">128</xref>], and resulting ineffective compensation, e.g., through frequent GP visits [<xref ref-type="bibr" rid="CR23">23</xref>]. Notably, a French study found that only 50% of adult patients without cognitive impairment were aware of the need for regular check-ups in TSC [<xref ref-type="bibr" rid="CR53">53</xref>]. This could be alleviated by the improvement of the transition from integrated pediatric to the commonly fragmented adult health care sector. Transition seems to be especially problematic regarding psychiatric problems [<xref ref-type="bibr" rid="CR53">53</xref>]. In all patients, transition should be guided towards specialized integrated TSC centers. This is especially true for those who are more severely affected, in whom regular screening (e.g. MRI) may be more difficult.</p>
</sec>
<sec id="Sec22">
<title>Direct costs</title>
<p id="Par51">TSC patients incur higher costs than the general population due to the chronic and multisystem nature of their disorder. In general, costs are at least twice as high as in the general population. These higher direct costs are due to variety of reasons, among them being higher in- and outpatient care use and the involvement of complicated medical operations such as brain surgery and renal procedures. Costs rise with the number of affected organ systems. Pulmonary complications from LAM can also result in substantial costs, although these complications are rare overall. Integrated care at TSC centers is a plausible strategy to reduce costs by eliminating wasteful diagnostics and reducing complications of TSC, but no data exist yet to support this notion. Data from a UK study [<xref ref-type="bibr" rid="CR23">23</xref>] suggest that the loss of multidisciplinary care, which often occurs during transition, significantly reduces the quality and efficiency of medical care. To date, there is a dearth of studies directly evaluating the potential cost benefit and improvement in terms of HRCU of centralized care at TSC clinics. While 10 studies mentioned the share of patients treated at a TSC center, no explicit outcome in differences were reported. Especially, the benefits in the long-term treatment have not been adequately assessed in the presently available studies. This is equally true for studies focusing on the cost of neurosurgical interventions. One study calculating projected costs found that epilepsy surgery is a cost-effective treatment option in high-resource environments [<xref ref-type="bibr" rid="CR109">109</xref>].</p>
</sec>
<sec id="Sec23">
<title>Individual and caregiver quality of life</title>
<p id="Par52">While it is difficult to assess an individual subjective BOI or to directly compare BOI from different organ manifestations ins TSC, neurological and psychiatric manifestations play an important role for individuals with TSC and their caregivers. Quality of life was significantly worse for those with epilepsy than with only renal AML in one study [<xref ref-type="bibr" rid="CR121">121</xref>]. Quality of life is severely affected by lower cognitive functioning and pharmacoresistant epilepsy [<xref ref-type="bibr" rid="CR121">121</xref>–<xref ref-type="bibr" rid="CR123">123</xref>]. Everolimus has recently been approved as a specific disease-modifying drug in TSC and first results are encouraging regarding the reduction of BOI in some indications [<xref ref-type="bibr" rid="CR103">103</xref>]. The same is true for epilepsy surgery [<xref ref-type="bibr" rid="CR101">101</xref>]. Multimodal approaches should be used to identify more pharmacoresistant epilepsy candidates for surgery.</p>
<p id="Par53">Caregivers are particularly burdened by caring for individuals affected by more severe forms of epilepsy such as West syndrome and correlating neurological and psychiatric manifestations [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. Against this background, it is surprising that, according to the results of the TOSCA study, neuropsychiatric symptoms in TSC patients remain incompletely assessed. The use of the TAND checklist developed by de Vries et al. [<xref ref-type="bibr" rid="CR82">82</xref>] can possibly remedy this situation and lead to a better psychological and psychiatric care of the affected TSC patients. Caregivers seems to miss a high amount of work time, but unfortunately, data on this is sparse. Indirect costs should be a focus of further research. Caregiver burden should be openly discussed in an appropriate setting and help could be offered, e.g., by identifying and closing gaps in psychosocial support. Referral to patient advocacy groups may also be appropriate in many cases.</p>
<p id="Par54">While it may be obvious to the practitioner that more severe manifestations of TSC, especially in the neurological and psychiatric domains, are severely stressful for the patient and his caregivers, there could be a discrepancy between the priority of symptoms for the individual and the external medical perspective regarding other manifestations. Skin lesions may not be seen as particularly grave but were among the most bothersome signs for adults with TSC in one study. Consequently, the treatment of facial angiofibroma improved QoL [<xref ref-type="bibr" rid="CR108">108</xref>]. Thus, practitioners should openly discuss skin manifestations with the patient and refer them to appropriate dermatological care.</p>
<p id="Par55">Mortality is significantly increased in TSC patients. When aggregating all published mortality data in TSC patients, we found that the most common causes of death were SUDEP, kidney complications, and complications from systemic infections. The high rate of SUDEP deaths may be explained by a high rate of drug-refractory epilepsy, which is a major risk factor of SUDEP. The risk of SUDEP should be discussed with patients with epilepsy and their caregivers in an appropriate setting [<xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]. Infections such as aspiration pneumonia common in one study [<xref ref-type="bibr" rid="CR104">104</xref>] can be sequelae of bilateral tonic-clonic seizures.</p>
</sec>
</sec>
<sec id="Sec24">
<title>Conclusions</title>
<p id="Par56">Individuals with TSC and their caregivers share a high burden of disease, which is higher than in many other chronic diseases. Quality of life is reduced especially in those with pharmacoresistant epilepsy and reduced cognitive functioning. While individuals with TSC require a considerable amount of medical care, gaps in screening and treatment are apparent, especially regarding the treatment of TSC-associated neuropsychological disorders. Recent advancements in targeted therapy by mTOR inhibitors and epilepsy surgery can reduce the burden of illness and the effectiveness of these therapies should be a focus of further research. Care for individuals with TSC should be organized through specialized TSC centers and their effectiveness at reducing the burden of illness and costs should be investigated. Lastly, finding common tests and protocols to assess the burden of illness in TSC would facilitate research and comparison in this heterogeneous and multifaceted disorder.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>JPZ and AS developed the idea for this study. JPZ and AS conceived the paper, collected the data, and performed statistical analysis. JPZ created the charts and figures. All authors wrote the paper, discussed the results, contributed to the final manuscript, and approved the final manuscript for publication.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This study was supported by a LOEWE Grant from the State of Hessen for the “Center for Personalized Translational Epilepsy Research” (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets analysed during the current study available from the corresponding author on reasonable request.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par57">Not applicable.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par58">Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par59">JPZ reports a speaker’s honorarium from Eisai.</p>
<p id="Par60">DNF reports travel support and honoraria from Novartis. His employer has also received support for clinical trials and consulting work from Novartis.</p>
<p id="Par61">RN reports speakers and board fees from GW Pharma, Biocodex, Novartis, Eisai, Nutricia, Zogenix, UCB, Advicenne, Biogene, Stoke and unrestricted educational grants from UCB, Eisai and GW Pharma.</p>
<p id="Par62">FR reports personal fees from Eisai, GW-Pharma and Desitin Pharma, personal fees and others from Novartis, personal fees from Medtronic, personal fees from Cerbomed, personal fees from Shire, grants from the European Union, the German Minister for Education and Research (BMBF) the LOEWE Programm of the state of Hesse and grants from the Deutsche Forschungsgemeinschaft (DFG) and the Detlev-Wrobel-Fonds for Epilepsy Research .</p>
<p id="Par63">MS reports personal fees and grants from Novartis.</p>
<p id="Par64">SSB reports personal fees from UCB, Desitin Arzneimittel, Novartis, Zogenix, LivaNova, and Eisai.</p>
<p id="Par65">AWK reports grants and personal fees from Novartis and Nutricia, and only personal fees from Desitin Arzneimittel, Dr. Schär, Vitaflo, UCB Pharma.</p>
<p id="Par66">AS reports personal fees and grants from Desitin Arzneimittel, Eisai, GW pharmaceuticals, LivaNova, Marinus pharmaceuticals, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix.</p>
<p id="Par67">CH declares that he has no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Epidemiology of tuberous sclerosis</article-title>
<source/>Ann N Y Acad Sci
          <year>1991</year>
<volume>615</volume>
<fpage>125</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1991.tb37754.x</pub-id>
<pub-id pub-id-type="pmid">2039137</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Scahill</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Genetic aspects of tuberous sclerosis in the west of Scotland</article-title>
<source/>J Med Genet
          <year>1989</year>
<volume>26</volume>
<issue>1</issue>
<fpage>28</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.26.1.28</pub-id>
<pub-id pub-id-type="pmid">2918523</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devlin</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland</article-title>
<source/>Dev Med Child Neurol
          <year>2006</year>
<volume>48</volume>
<issue>6</issue>
<fpage>495</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162206001058</pub-id>
<pub-id pub-id-type="pmid">16700943</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Shiell</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>CN</given-names>
</name>
</person-group>
<article-title>Prevalence of tuberous sclerosis estimated by capture-recapture analysis</article-title>
<source/>Lancet (London, England)
          <year>1998</year>
<volume>351</volume>
<issue>9114</issue>
<fpage>1490</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)78872-3</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<mixed-citation publication-type="other">Hong CH, Tu HP, Lin JR, Lee CH. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010). Br J Dermatol. 2016;174(6):1282–9.</mixed-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiederholt</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kurland</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982</article-title>
<source/>Neurology
          <year>1985</year>
<volume>35</volume>
<issue>4</issue>
<fpage>600</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.35.4.600</pub-id>
<pub-id pub-id-type="pmid">3982655</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahlsen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Lindblom</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis in Western Sweden. A population study of cases with early childhood onset</article-title>
<source/>Arch Neurol
          <year>1994</year>
<volume>51</volume>
<issue>1</issue>
<fpage>76</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1994.00540130110018</pub-id>
<pub-id pub-id-type="pmid">8274113</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Darling</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study</article-title>
<source/>Neuroepidemiology
          <year>2009</year>
<volume>33</volume>
<issue>4</issue>
<fpage>335</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1159/000254569</pub-id>
<pub-id pub-id-type="pmid">19887839</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kurland</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Whisnant</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989</article-title>
<source/>Arch Neurol
          <year>1991</year>
<volume>48</volume>
<issue>4</issue>
<fpage>400</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1991.00530160068015</pub-id>
<pub-id pub-id-type="pmid">2012513</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancak</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goedbloed</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elfferich</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wouters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maat-Kievit</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Verhoef</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van den Ouweland</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex</article-title>
<source/>Eur J Hum Genet
          <year>2005</year>
<volume>13</volume>
<issue>6</issue>
<fpage>731</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201402</pub-id>
<pub-id pub-id-type="pmid">15798777</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Drummond</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Sculpher</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Torrance</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Stoddart</surname>
<given-names>GL</given-names>
</name>
</person-group>
<source/>Methods for the economic evaluation of health care programme
          <year>2005</year>
<edition>3</edition>
<publisher-loc>Oxford</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<mixed-citation publication-type="other">Willems LM, Richter S, Watermann N, Bauer S, Klein KM, Reese JP, Schöffski O, Hamer HM, Knake S, Rosenow F, Strzelczyk A. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 — A ten-year overview. Epilepsy Behav. 2018;83:28–35.</mixed-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<mixed-citation publication-type="other">Strzelczyk A, Schubert‐Bast S, Bast T, Bettendorf U, Fiedler B, Hamer HM, Herting A, Kalski M, Kay L, Kieslich M, et al. A multicenter, matched case‐control analysis comparing burden‐of‐illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia. 2019;60(8):1697–710.</mixed-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<mixed-citation publication-type="other">Riechmann J, Willems LM, Boor R, Kieslich M, Knake S, Langner C, Neubauer BA, Oberman B, Philippi H, Reese JP, et al. Quality of life and correlating factors in children, adolescents with epilepsy, and their caregivers: A cross-sectional multicenter study from Germany. Seizure. 2019;69:92–8.</mixed-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallett</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Blieden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valentim</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review</article-title>
<source/>Curr Med Res Opin
          <year>2011</year>
<volume>27</volume>
<issue>8</issue>
<fpage>1571</fpage>
<lpage>1583</lpage>
<pub-id pub-id-type="doi">10.1185/03007995.2011.586687</pub-id>
<pub-id pub-id-type="pmid">21692602</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henske</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex</article-title>
<source/>Nat Rev Dis Primers
          <year>2016</year>
<volume>2</volume>
<fpage>16035</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2016.35</pub-id>
<pub-id pub-id-type="pmid">27226234</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DG</given-names>
</name>
<collab>Group P</collab>
</person-group>
<article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>
<source/>BMJ (Clinical research ed)
          <year>2009</year>
<volume>339</volume>
<fpage>b2535</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.b2535</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strzelczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reese</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dodel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Cost of epilepsy: a systematic review</article-title>
<source/>Pharmacoeconomics
          <year>2008</year>
<volume>26</volume>
<issue>6</issue>
<fpage>463</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.2165/00019053-200826060-00002</pub-id>
<pub-id pub-id-type="pmid">18489198</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<mixed-citation publication-type="other">OECD.Stat Web database, 10.1787/data-00285-en, date accessed: June 2019.</mixed-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<mixed-citation publication-type="other">Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, Jansen AC, Jóźwiak S, Nabbout R, Sauter M, et al. TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis. 2014;9:182.</mixed-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>d'Augeres</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Castellana</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cottin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dahlin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients</article-title>
<source/>Orphanet J Rare Dis
          <year>2017</year>
<volume>12</volume>
<issue>1</issue>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-016-0553-5</pub-id>
<pub-id pub-id-type="pmid">28057044</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu-Shore</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Major</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Camposano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muzykewicz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>The natural history of epilepsy in tuberous sclerosis complex</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<issue>7</issue>
<fpage>1236</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02474.x</pub-id>
<pub-id pub-id-type="pmid">20041940</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koepp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Myland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miglio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Siva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Neary</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD)</article-title>
<source/>BMJ Open
          <year>2017</year>
<volume>7</volume>
<issue>10</issue>
<fpage>e015236</fpage>
<pub-id pub-id-type="doi">10.1136/bmjopen-2016-015236</pub-id>
<pub-id pub-id-type="pmid">28982809</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lennert</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Farrelly</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pira</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study</article-title>
<source/>J Child Neurol
          <year>2013</year>
<volume>28</volume>
<issue>4</issue>
<fpage>461</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.1177/0883073812448437</pub-id>
<pub-id pub-id-type="pmid">22772159</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex</article-title>
<source/>Epilepsia
          <year>2016</year>
<volume>57</volume>
<issue>9</issue>
<fpage>1443</fpage>
<lpage>1449</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13467</pub-id>
<pub-id pub-id-type="pmid">27417921</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nabbout</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benedik</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cottin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dahlin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D’Amato</surname>
<given-names>L</given-names>
</name>
<name>
<surname>d’Augeres</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in tuberous sclerosis complex: findings from the TOSCA study</article-title>
<source/>Epilepsia Open
          <year>2019</year>
<volume>4</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1002/epi4.12286</pub-id>
<pub-id pub-id-type="pmid">30868117</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welin</surname>
<given-names>KO</given-names>
</name>
<name>
<surname>Carlqvist</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Althin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eklund</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rask</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Epilepsy in tuberous sclerosis patients in Sweden - healthcare utilization, treatment, morbidity, and mortality using national register data</article-title>
<source/>Seizure
          <year>2017</year>
<volume>53</volume>
<fpage>4</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2017.10.005</pub-id>
<pub-id pub-id-type="pmid">29078087</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabora</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Nieto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choy</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Egelhoff</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs</article-title>
<source/>Am J Hum Genet
          <year>2001</year>
<volume>68</volume>
<issue>1</issue>
<fpage>64</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1086/316951</pub-id>
<pub-id pub-id-type="pmid">11112665</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukushima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Long-term follow-up study of west syndrome associated with tuberous sclerosis</article-title>
<source/>Brain Dev
          <year>2001</year>
<volume>23</volume>
<issue>7</issue>
<fpage>698</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="doi">10.1016/S0387-7604(01)00275-3</pub-id>
<pub-id pub-id-type="pmid">11701281</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukushima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Long-term course of west syndrome associated with tuberous sclerosis</article-title>
<source/>Epilepsia
          <year>1998</year>
<volume>39</volume>
<issue>Suppl 5</issue>
<fpage>50</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1998.tb05151.x</pub-id>
<pub-id pub-id-type="pmid">9737446</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Calder</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Mowat</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review</article-title>
<source/>Rev Neurosci
          <year>2018</year>
<volume>29</volume>
<issue>3</issue>
<fpage>295</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1515/revneuro-2017-0027</pub-id>
<pub-id pub-id-type="pmid">29211682</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adriaensen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Schaefer-Prokop</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Stijnen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Duyndam</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Prokop</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature</article-title>
<source/>Eur J Neurol
          <year>2009</year>
<volume>16</volume>
<issue>6</issue>
<fpage>691</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02567.x</pub-id>
<pub-id pub-id-type="pmid">19236458</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Renowden</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Noakes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Presdee</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study</article-title>
<source/>Arch Dis Child
          <year>2008</year>
<volume>93</volume>
<issue>9</issue>
<fpage>751</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1136/adc.2007.125880</pub-id>
<pub-id pub-id-type="pmid">18456692</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benedik</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cottin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>D'Amato</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beaure d'Augeres</surname>
<given-names>G</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Newly diagnosed and growing subependymal giant cell astrocytoma in adults with tuberous sclerosis complex: results from the international TOSCA Study</article-title>
<source/>Front Neurol
          <year>2019</year>
<volume>10</volume>
<fpage>821</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2019.00821</pub-id>
<pub-id pub-id-type="pmid">31428037</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vekeman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Magestro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Duh</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>T</given-names>
</name>
<name>
<surname>van Waalwijk van Doorn-Khosrovani</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs</article-title>
<source/>J Med Econ
          <year>2015</year>
<volume>18</volume>
<issue>12</issue>
<fpage>1060</fpage>
<lpage>1070</lpage>
<pub-id pub-id-type="doi">10.3111/13696998.2015.1075995</pub-id>
<pub-id pub-id-type="pmid">26201433</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2007</year>
<volume>16</volume>
<issue>1</issue>
<fpage>16</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-006-0570-3</pub-id>
<pub-id pub-id-type="pmid">17268883</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindenbaum</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis: a new estimate of prevalence within the Oxford region</article-title>
<source/>J Med Genet
          <year>1984</year>
<volume>21</volume>
<issue>4</issue>
<fpage>272</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.21.4.272</pub-id>
<pub-id pub-id-type="pmid">6492092</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex</article-title>
<source/>Psychol Med
          <year>2003</year>
<volume>33</volume>
<issue>2</issue>
<fpage>335</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291702007092</pub-id>
<pub-id pub-id-type="pmid">12622312</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>McKinlay</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Care of adolescents with severe learning disability from tuberous sclerosis</article-title>
<source/>Dev Med Child Neurol
          <year>2002</year>
<volume>44</volume>
<issue>4</issue>
<fpage>256</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162201002031</pub-id>
<pub-id pub-id-type="pmid">11995894</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Fiser</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex</article-title>
<source/>Ann Clin Psychiatry
          <year>2011</year>
<volume>23</volume>
<issue>4</issue>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">22073383</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toldo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brasson</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Miscioscia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pelizza</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Manara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mantegazza</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vecchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nosadini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gatta</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study</article-title>
<source/>Dev Med Child Neurol
          <year>2019</year>
<volume>61</volume>
<issue>2</issue>
<fpage>168</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.14055</pub-id>
<pub-id pub-id-type="pmid">30298907</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Harland</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Spink</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Demuth</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lucchese</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the clinical practice research Datalink (CPRD)</article-title>
<source/>Eur J Paediatr Neurol
          <year>2016</year>
<volume>20</volume>
<issue>2</issue>
<fpage>296</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2015.11.011</pub-id>
<pub-id pub-id-type="pmid">26706603</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillberg</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ahlsen</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study</article-title>
<source/>Dev Med Child Neurol
          <year>1994</year>
<volume>36</volume>
<issue>1</issue>
<fpage>50</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1994.tb11765.x</pub-id>
<pub-id pub-id-type="pmid">8132114</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vignoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>La Briola</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Peron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vannicola</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Saccani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magnaghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Scornavacca</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Canevini</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers</article-title>
<source/>Orphanet J Rare Dis
          <year>2015</year>
<volume>10</volume>
<fpage>154</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-015-0371-1</pub-id>
<pub-id pub-id-type="pmid">26631248</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muzykewicz</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Newberry</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Danforth</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex</article-title>
<source/>Epilepsy Behav
          <year>2007</year>
<volume>11</volume>
<issue>4</issue>
<fpage>506</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2007.07.010</pub-id>
<pub-id pub-id-type="pmid">17936687</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A prevalence study of autism in tuberous sclerosis</article-title>
<source/>J Autism Dev Disord
          <year>1993</year>
<volume>23</volume>
<issue>2</issue>
<fpage>323</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1007/BF01046223</pub-id>
<pub-id pub-id-type="pmid">8331050</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Piven</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Autism and tuberous sclerosis complex: prevalence and clinical features</article-title>
<source/>J Autism Dev Disord
          <year>1998</year>
<volume>28</volume>
<issue>4</issue>
<fpage>279</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="doi">10.1023/A:1026004501631</pub-id>
<pub-id pub-id-type="pmid">9711484</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Porfirio</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Manzi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Seri</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Autism in tuberous sclerosis</article-title>
<source/>Eur J Paediatr Neurol
          <year>2004</year>
<volume>8</volume>
<issue>6</issue>
<fpage>327</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2004.08.005</pub-id>
<pub-id pub-id-type="pmid">15542389</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raznahan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis</article-title>
<source/>J Intellect Disabil Res
          <year>2006</year>
<volume>50</volume>
<issue>Pt 8</issue>
<fpage>561</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2788.2006.00828.x</pub-id>
<pub-id pub-id-type="pmid">16867063</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benedik</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cottin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dahlin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D'Amato</surname>
<given-names>L</given-names>
</name>
<name>
<surname>d'Augeres</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study</article-title>
<source/>Orphanet J Rare Dis
          <year>2018</year>
<volume>13</volume>
<issue>1</issue>
<fpage>157</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-018-0901-8</pub-id>
<pub-id pub-id-type="pmid">30201051</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilde</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eden</surname>
<given-names>K</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Welham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Self-injury and aggression in adults with tuberous sclerosis complex: frequency, associated person characteristics, and implications for assessment</article-title>
<source/>Res Dev Disabil
          <year>2017</year>
<volume>64</volume>
<fpage>119</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.ridd.2017.03.007</pub-id>
<pub-id pub-id-type="pmid">28411579</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mous</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Overwater</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Vidal Gato</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duvekot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ten Hoopen</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Lequin</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Dieleman</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Cortical dysplasia and autistic trait severity in children with tuberous sclerosis complex: a clinical epidemiological study</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2018</year>
<volume>27</volume>
<issue>6</issue>
<fpage>753</fpage>
<lpage>765</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-017-1066-z</pub-id>
<pub-id pub-id-type="pmid">29063203</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ghobeira</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Azzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ville</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Riquet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Touraine</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chemaly</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nabbout</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Experience of follow-up, quality of life, and transition from pediatric to adult healthcare of patients with tuberous sclerosis complex</article-title>
<source/>Epilepsy Behav
          <year>2019</year>
<volume>96</volume>
<fpage>23</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2019.04.027</pub-id>
<pub-id pub-id-type="pmid">31077938</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Genotype and psychological phenotype in tuberous sclerosis</article-title>
<source/>J Med Genet
          <year>2004</year>
<volume>41</volume>
<issue>3</issue>
<fpage>203</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2003.012757</pub-id>
<pub-id pub-id-type="pmid">14985384</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pulsifer</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Winterkorn</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Psychological profile of adults with tuberous sclerosis complex</article-title>
<source/>Epilepsy Behavior
          <year>2007</year>
<volume>10</volume>
<issue>3</issue>
<fpage>402</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2007.02.004</pub-id>
<pub-id pub-id-type="pmid">17392032</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Skalicky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Magestro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prestifilippo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex: a survey of health care resource use and health burden</article-title>
<source/>Pediatr Neurol
          <year>2015</year>
<volume>52</volume>
<issue>4</issue>
<fpage>435</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.11.013</pub-id>
<pub-id pub-id-type="pmid">25771998</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<mixed-citation publication-type="other">Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D’Amato L, d’Augeres GB, de Vries PJ, et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease awareness. Nephrol Dial Transplant. 2019;34(3):502-8.</mixed-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<mixed-citation publication-type="other">Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y, Jiang Z, Oliva E, Jóźwiak S, Nussbaum RL, et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. 2014;38(7):895–909.</mixed-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Devesa</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fraumeni</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Rising incidence of renal cell cancer in the United States</article-title>
<source/>JAMA
          <year>1999</year>
<volume>281</volume>
<issue>17</issue>
<fpage>1628</fpage>
<lpage>1631</lpage>
<pub-id pub-id-type="doi">10.1001/jama.281.17.1628</pub-id>
<pub-id pub-id-type="pmid">10235157</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bissler</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Christopher Kingswood</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Renal manifestation of tuberous sclerosis complex</article-title>
<source/>Am J Med Genet C: Semin Med Genet
          <year>2018</year>
<volume>178</volume>
<issue>3</issue>
<fpage>338</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.c.31654</pub-id>
<pub-id pub-id-type="pmid">30307110</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rakowski</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Winterkorn</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors</article-title>
<source/>Kidney Int
          <year>2006</year>
<volume>70</volume>
<issue>10</issue>
<fpage>1777</fpage>
<lpage>1782</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ki.5001853</pub-id>
<pub-id pub-id-type="pmid">17003820</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adriaensen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Schaefer-Prokop</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Duyndam</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Prokop</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex</article-title>
<source/>Clin Radiol
          <year>2011</year>
<volume>66</volume>
<issue>7</issue>
<fpage>625</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="doi">10.1016/j.crad.2011.02.009</pub-id>
<pub-id pub-id-type="pmid">21459371</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cudzilo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Szczesniak</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Brody</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Rattan</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Bissler</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LR</given-names>
</name>
</person-group>
<article-title>Lymphangioleiomyomatosis screening in women with tuberous sclerosis</article-title>
<source/>Chest
          <year>2013</year>
<volume>144</volume>
<issue>2</issue>
<fpage>578</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1378/chest.12-2813</pub-id>
<pub-id pub-id-type="pmid">23539171</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jost</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gloviczki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Stanson</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Pairolero</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Aortic aneurysms in children and young adults with tuberous sclerosis: report of two cases and review of the literature</article-title>
<source/>J Vasc Surg
          <year>2001</year>
<volume>33</volume>
<issue>3</issue>
<fpage>639</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1067/mva.2001.111976</pub-id>
<pub-id pub-id-type="pmid">11241138</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<mixed-citation publication-type="other">Jóźwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37(12):911–7.</mixed-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowley</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Ophthalmic manifestations of tuberous sclerosis: a population based study</article-title>
<source/>Br J Ophthalmol
          <year>2001</year>
<volume>85</volume>
<issue>4</issue>
<fpage>420</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1136/bjo.85.4.420</pub-id>
<pub-id pub-id-type="pmid">11264130</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<mixed-citation publication-type="other">Jóźwiak S, Pedich M, Rajszys P, Michalowicz R. Incidence of hepatic hamartomas in tuberous sclerosis. Arch Dis Child. 1992;67(11):1363–5.</mixed-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Hedgire</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Camposano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Harisinghani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis</article-title>
<source/>Clin Genet
          <year>2012</year>
<volume>82</volume>
<issue>6</issue>
<fpage>552</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01845.x</pub-id>
<pub-id pub-id-type="pmid">22251200</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Hedgire</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Deshpande</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stemmer-Rachamimov</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Harisinghani</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ferrone</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex</article-title>
<source/>Clin Genet
          <year>2012</year>
<volume>82</volume>
<issue>6</issue>
<fpage>558</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01805.x</pub-id>
<pub-id pub-id-type="pmid">22035404</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Karas</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>Central nervous system manifestations of tuberous sclerosis complex</article-title>
<source/>Am J Med Genet C: Semin Med Genet
          <year>2018</year>
<volume>178</volume>
<issue>3</issue>
<fpage>291</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.c.31647</pub-id>
<pub-id pub-id-type="pmid">30230171</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Neurological and neuropsychiatric aspects of tuberous sclerosis complex</article-title>
<source/>Lancet Neurol
          <year>2015</year>
<volume>14</volume>
<issue>7</issue>
<fpage>733</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00069-1</pub-id>
<pub-id pub-id-type="pmid">26067126</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capal</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Bernardino-Cuesta</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Byars</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Bing</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Kent</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Influence of seizures on early development in tuberous sclerosis complex</article-title>
<source/>Epilepsy Behav
          <year>2017</year>
<volume>70</volume>
<issue>Pt A</issue>
<fpage>245</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2017.02.007</pub-id>
<pub-id pub-id-type="pmid">28457992</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<mixed-citation publication-type="other">Jóźwiak S, Goodman M, Lamm SH. Poor mental development in patients with tuberous sclerosis complex: clinical risk factors. Arch Neurol. 1998;55(3):379–84.</mixed-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Eeghen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chu-Shore</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Pulsifer</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Camposano</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Cognitive and adaptive development of patients with tuberous sclerosis complex: a retrospective, longitudinal investigation</article-title>
<source/>Epilepsy Behav
          <year>2012</year>
<volume>23</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2011.10.005</pub-id>
<pub-id pub-id-type="pmid">22099526</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Overwater</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Verhaar</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Lingsma</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Bindels-de Heus</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>van den Ouweland</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ten Hoopen</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Moll</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex</article-title>
<source/>J Neurol
          <year>2017</year>
<volume>264</volume>
<issue>1</issue>
<fpage>161</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-016-8335-5</pub-id>
<pub-id pub-id-type="pmid">27878438</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bombardieri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pinci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cerminara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Early control of seizures improves long-term outcome in children with tuberous sclerosis complex</article-title>
<source/>Eur J Paediatr Neurol
          <year>2010</year>
<volume>14</volume>
<issue>2</issue>
<fpage>146</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2009.03.003</pub-id>
<pub-id pub-id-type="pmid">19369101</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<mixed-citation publication-type="other">Jóźwiak S, Kotulska K, Domanska-Pakiela D, Lojszczyk B, Syczewska M, Chmielewski D, Dunin-Wasowicz D, Kmiec T, Szymkiewicz-Dangel J, Kornacka M, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15(5):424–31.</mixed-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fombonne</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Du Mazaubrun</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grandjean</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Autism and associated medical disorders in a French epidemiological survey</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1997</year>
<volume>36</volume>
<issue>11</issue>
<fpage>1561</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="pmid">9394941</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stores</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Sleep disorder and epilepsy in children with tuberous sclerosis: a questionnaire-based study</article-title>
<source/>Dev Med Child Neurol
          <year>1994</year>
<volume>36</volume>
<issue>2</issue>
<fpage>108</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1994.tb11819.x</pub-id>
<pub-id pub-id-type="pmid">7510655</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Cognitive deficits in normally intelligent patients with tuberous sclerosis</article-title>
<source/>Am J Med Genet
          <year>1999</year>
<volume>88</volume>
<issue>6</issue>
<fpage>642</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19991215)88:6&lt;642::AID-AJMG12&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">10581483</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boronat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Van Eeghen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Shinnick</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Newberry</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Stressor-related disorders in tuberous sclerosis</article-title>
<source/>Ann Clin Psychiatry
          <year>2013</year>
<volume>25</volume>
<issue>4</issue>
<fpage>243</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">23926580</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Whittemore</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Leclezio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Byars</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ess</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Hook</surname>
<given-names>D</given-names>
</name>
<name>
<surname>King</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist</article-title>
<source/>Pediatr Neurol
          <year>2015</year>
<volume>52</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.10.004</pub-id>
<pub-id pub-id-type="pmid">25532776</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Noakes</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>An epidemiological study of renal pathology in tuberous sclerosis complex</article-title>
<source/>BJU Int
          <year>2004</year>
<volume>94</volume>
<issue>6</issue>
<fpage>853</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="doi">10.1111/j.1464-410X.2004.05046.x</pub-id>
<pub-id pub-id-type="pmid">15476522</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ewalt</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sparagana</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Roach</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Renal lesion growth in children with tuberous sclerosis complex</article-title>
<source/>J Urol
          <year>1998</year>
<volume>160</volume>
<issue>1</issue>
<fpage>141</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-5347(01)63072-6</pub-id>
<pub-id pub-id-type="pmid">9628635</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cockerell</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Guenin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heimdal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bjornvold</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Selmer</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Rouviere</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Prevalence of renal Angiomyolipomas and spontaneous bleeding related to Angiomyolipomas in tuberous sclerosis complex patients in France and Norway-a questionnaire study</article-title>
<source/>Urology
          <year>2017</year>
<volume>104</volume>
<fpage>70</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1016/j.urology.2017.02.023</pub-id>
<pub-id pub-id-type="pmid">28232177</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eijkemans</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>van der Wal</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Reijnders</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Roes</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>van Waalwijk van Doorn-Khosrovani</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Magestro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zonnenberg</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Long-term follow-up assessing renal Angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands</article-title>
<source/>Am J Kidney Dis
          <year>2015</year>
<volume>66</volume>
<issue>4</issue>
<fpage>638</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1053/j.ajkd.2015.05.016</pub-id>
<pub-id pub-id-type="pmid">26165440</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Kabala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>A population study of renal disease in patients with tuberous sclerosis</article-title>
<source/>Br J Urol
          <year>1994</year>
<volume>74</volume>
<issue>2</issue>
<fpage>151</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1111/j.1464-410X.1994.tb16577.x</pub-id>
<pub-id pub-id-type="pmid">7921930</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hancock</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kingswood</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>End-stage renal failure in adults with the tuberous sclerosis complex</article-title>
<source/>Nephrol Dial Transplant
          <year>1999</year>
<volume>14</volume>
<issue>4</issue>
<fpage>988</fpage>
<lpage>991</lpage>
<pub-id pub-id-type="doi">10.1093/ndt/14.4.988</pub-id>
<pub-id pub-id-type="pmid">10328488</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schillinger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Montagnac</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Chronic renal failure and its treatment in tuberous sclerosis</article-title>
<source/>Nephrol Dial Transplant
          <year>1996</year>
<volume>11</volume>
<issue>3</issue>
<fpage>481</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.ndt.a027315</pub-id>
<pub-id pub-id-type="pmid">8671819</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isaacs</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Perinatal (fetal and neonatal) tuberous sclerosis: a review</article-title>
<source/>Am J Perinatol
          <year>2009</year>
<volume>26</volume>
<issue>10</issue>
<fpage>755</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="doi">10.1055/s-0029-1223267</pub-id>
<pub-id pub-id-type="pmid">19452429</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kocabas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cetin</surname>
<given-names>II</given-names>
</name>
<name>
<surname>Emir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Ari</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Degerliyurt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guven</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Cardiac rhabdomyomas associated with tuberous sclerosis complex in 11 children: presentation to outcome</article-title>
<source/>Pediatr Hematol Oncol
          <year>2013</year>
<volume>30</volume>
<issue>2</issue>
<fpage>71</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.3109/08880018.2012.734896</pub-id>
<pub-id pub-id-type="pmid">23151153</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bader</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Chitayat</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Smallhorn</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Toi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hornberger</surname>
<given-names>LK</given-names>
</name>
</person-group>
<article-title>Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex</article-title>
<source/>J Pediatr
          <year>2003</year>
<volume>143</volume>
<issue>5</issue>
<fpage>620</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1067/S0022-3476(03)00494-3</pub-id>
<pub-id pub-id-type="pmid">14615733</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamzu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Achiron</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hegesh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rabinowitz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Auslander</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yagel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zalel</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluating the risk of tuberous sclerosis in cases with prenatal diagnosis of cardiac rhabdomyoma</article-title>
<source/>Prenat Diagn
          <year>2002</year>
<volume>22</volume>
<issue>11</issue>
<fpage>1044</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1002/pd.464</pub-id>
<pub-id pub-id-type="pmid">12424773</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>The cutaneous features of tuberous sclerosis: a population study</article-title>
<source/>Br J Dermatol
          <year>1996</year>
<volume>135</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2133.1996.tb03597.x</pub-id>
<pub-id pub-id-type="pmid">8776349</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flanagan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>McCartan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McMenamin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Developmental enamel defects in tuberous sclerosis: a clinical genetic marker?</article-title>
<source/>J Med Genet
          <year>1997</year>
<volume>34</volume>
<issue>8</issue>
<fpage>637</fpage>
<lpage>639</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.34.8.637</pub-id>
<pub-id pub-id-type="pmid">9279754</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aronow</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traboulsi</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex: genotype/phenotype correlation of retinal findings</article-title>
<source/>Ophthalmology
          <year>2012</year>
<volume>119</volume>
<issue>9</issue>
<fpage>1917</fpage>
<lpage>1923</lpage>
<pub-id pub-id-type="doi">10.1016/j.ophtha.2012.03.020</pub-id>
<pub-id pub-id-type="pmid">22608477</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boronat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Sclerotic bone lesions in tuberous sclerosis complex: a genotype-phenotype study</article-title>
<source/>Am J Med Genet A
          <year>2017</year>
<volume>173</volume>
<issue>7</issue>
<fpage>1891</fpage>
<lpage>1895</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.38260</pub-id>
<pub-id pub-id-type="pmid">28488386</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boronat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Caruso</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cerebellar lesions are associated with TSC2 mutations in tuberous sclerosis complex: a retrospective record review study</article-title>
<source/>Dev Med Child Neurol
          <year>2017</year>
<volume>59</volume>
<issue>10</issue>
<fpage>1071</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.13499</pub-id>
<pub-id pub-id-type="pmid">28786492</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nabbout</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neary</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Herbst</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sully</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brohan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Measuring health-related quality of life in tuberous sclerosis complex - psychometric evaluation of three instruments in individuals with refractory epilepsy</article-title>
<source/>Front Pharmacol
          <year>2018</year>
<volume>9</volume>
<fpage>964</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2018.00964</pub-id>
<pub-id pub-id-type="pmid">30214408</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lie</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Crowson</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Causes of death in patients with tuberous sclerosis</article-title>
<source/>Mayo Clin Proc
          <year>1991</year>
<volume>66</volume>
<issue>8</issue>
<fpage>792</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1016/S0025-6196(12)61196-3</pub-id>
<pub-id pub-id-type="pmid">1861550</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<issue>11</issue>
<fpage>2316</fpage>
<lpage>2321</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02669.x</pub-id>
<pub-id pub-id-type="pmid">20633038</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graffigna</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bosio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cecchini</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Assisting a child with tuberous sclerosis complex (TSC): a qualitative deep analysis of parents’ experience and caring needs</article-title>
<source/>BMJ Open
          <year>2013</year>
<volume>3</volume>
<issue>12</issue>
<fpage>e003707</fpage>
<pub-id pub-id-type="doi">10.1136/bmjopen-2013-003707</pub-id>
<pub-id pub-id-type="pmid">24319280</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Wilfong</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Holland-Bouley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Everolimus treatment of refractory epilepsy in tuberous sclerosis complex</article-title>
<source/>Ann Neurol
          <year>2013</year>
<volume>74</volume>
<issue>5</issue>
<fpage>679</fpage>
<lpage>687</lpage>
<pub-id pub-id-type="doi">10.1002/ana.23960</pub-id>
<pub-id pub-id-type="pmid">23798472</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kristof</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Zhi Li</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Major</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Landry</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization</article-title>
<source/>Chest
          <year>2015</year>
<volume>148</volume>
<issue>2</issue>
<fpage>444</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1378/chest.14-3095</pub-id>
<pub-id pub-id-type="pmid">25789699</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Skalicky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Pashos</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Magestro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Prestifilippo</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Caring for children with tuberous sclerosis complex: what is the physical and mental health impact on caregivers?</article-title>
<source/>J Child Neurol
          <year>2015</year>
<volume>30</volume>
<issue>12</issue>
<fpage>1574</fpage>
<lpage>1581</lpage>
<pub-id pub-id-type="doi">10.1177/0883073815575364</pub-id>
<pub-id pub-id-type="pmid">25838447</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skalicky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Magestro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prestifilippo</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey</article-title>
<source/>J Child Neurol
          <year>2015</year>
<volume>30</volume>
<issue>5</issue>
<fpage>563</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1177/0883073814523318</pub-id>
<pub-id pub-id-type="pmid">24667738</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kohrman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study</article-title>
<source/>J Med Econ
          <year>2015</year>
<volume>18</volume>
<issue>5</issue>
<fpage>349</fpage>
<lpage>356</lpage>
<pub-id pub-id-type="doi">10.3111/13696998.2014.1001513</pub-id>
<pub-id pub-id-type="pmid">25525770</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crall</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dies</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Effect of Angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers</article-title>
<source/>Pediatr Dermatol
          <year>2016</year>
<volume>33</volume>
<issue>5</issue>
<fpage>518</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.1111/pde.12933</pub-id>
<pub-id pub-id-type="pmid">27436143</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fallah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weil</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baca</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Mathern</surname>
<given-names>GW</given-names>
</name>
</person-group>
<article-title>Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex</article-title>
<source/>Epilepsy Behav
          <year>2016</year>
<volume>63</volume>
<fpage>79</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.07.034</pub-id>
<pub-id pub-id-type="pmid">27591681</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Demuth</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Erhard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nasuti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Myland</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The economic burden of tuberous sclerosis complex in the UK: a retrospective cohort study in the clinical practice research datalink</article-title>
<source/>J Med Econ
          <year>2016</year>
<volume>19</volume>
<issue>11</issue>
<fpage>1087</fpage>
<lpage>1098</lpage>
<pub-id pub-id-type="doi">10.1080/13696998.2016.1199432</pub-id>
<pub-id pub-id-type="pmid">27267148</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingswood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Nasuti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Myland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Siva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD)</article-title>
<source/>J Med Econ
          <year>2016</year>
<volume>19</volume>
<issue>12</issue>
<fpage>1116</fpage>
<lpage>1126</lpage>
<pub-id pub-id-type="doi">10.1080/13696998.2016.1202254</pub-id>
<pub-id pub-id-type="pmid">27310569</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanweer</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lieber</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McDowell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Harter</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis health care utilization based on the national inpatient sample database: a review of 5655 hospitalizations</article-title>
<source/>World Neurosurg
          <year>2016</year>
<volume>91</volume>
<fpage>97</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.wneu.2016.03.043</pub-id>
<pub-id pub-id-type="pmid">27025453</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Calder</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Laugharne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Causes of mortality in individuals with tuberous sclerosis complex</article-title>
<source/>Dev Med Child Neurol
          <year>2017</year>
<volume>59</volume>
<issue>6</issue>
<fpage>612</fpage>
<lpage>617</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.13352</pub-id>
<pub-id pub-id-type="pmid">27935023</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cappell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Prestifilippo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hulbert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bissler</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma</article-title>
<source/>J Med Econ
          <year>2017</year>
<volume>20</volume>
<issue>4</issue>
<fpage>388</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1080/13696998.2016.1272461</pub-id>
<pub-id pub-id-type="pmid">27998195</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Both</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ten Holt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mous</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patist</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rietman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dieleman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ten Hoopen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vergeer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bindels-de Heus</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tuberous sclerosis complex: concerns and needs of patients and parents from the transitional period to adulthood</article-title>
<source/>Epilepsy Behav
          <year>2018</year>
<volume>83</volume>
<fpage>13</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2018.03.012</pub-id>
<pub-id pub-id-type="pmid">29631156</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<mixed-citation publication-type="other">Hamer HM, Pfäfflin M, Baier H, Bösebeck F, Franz M, Holtkamp M, Kurlemann G, May TW, Mayer T, Metzner M, et al. Characteristics and healthcare situation of adult patients with tuberous sclerosis complex in German epilepsy centers. Epilepsy Behav. 2018;82:64–7.</mixed-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopp</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Muzykewicz</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Staley</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Pulsifer</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Behavior problems in children with tuberous sclerosis complex and parental stress</article-title>
<source/>Epilepsy Behav
          <year>2008</year>
<volume>13</volume>
<issue>3</issue>
<fpage>505</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2008.05.010</pub-id>
<pub-id pub-id-type="pmid">18602868</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<mixed-citation publication-type="other">Mowrey KE, Ashfaq M, Pearson DA, Hashmi SS, Roberds SL, Farach LS, Northrup H. The impact of psychiatric symptoms on tuberous sclerosis complex and utilization of mental health treatment. Pediatr Neurol. 2019;91:41-9.</mixed-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skalicky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Economic burden, work, and school productivity in individuals with tuberous sclerosis and their families</article-title>
<source/>J Med Econ
          <year>2018</year>
<volume>21</volume>
<issue>10</issue>
<fpage>953</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.1080/13696998.2018.1487447</pub-id>
<pub-id pub-id-type="pmid">29890870</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Swallow</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Peeples</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meiselbach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Signorovitch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kohrman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy treatment patterns among patients with tuberous sclerosis complex</article-title>
<source/>J Neurol Sci
          <year>2018</year>
<volume>391</volume>
<fpage>104</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2018.06.011</pub-id>
<pub-id pub-id-type="pmid">30103955</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<mixed-citation publication-type="other">Amin S, Mallick AA, Lux A, O'Callaghan F. Quality of life in patients with tuberous sclerosis complex (TSC). Eur J Paediatr Neurol. 2019;23:801-7.</mixed-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tritton</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brohan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fladrowski</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Evanochko</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Neary</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Buffa</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: a web-based survey</article-title>
<source/>Epilepsy Behav
          <year>2019</year>
<volume>92</volume>
<fpage>213</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2018.11.021</pub-id>
<pub-id pub-id-type="pmid">30690322</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<mixed-citation publication-type="other">Vergeer M, de Ranitz-Greven W, Neary M, Ionescu-Ittu R, Emond B, Duh MS, Jansen F, Zonnenberg B. Epilepsy, impaired functioning and quality of life in patients with tuberous sclerosis complex. Epilepsia Open. 2019;4:581-92.</mixed-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mokhallati</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>W</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Szczesniak</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Lymphangioleiomyomatosis mortality in patients with tuberous sclerosis complex</article-title>
<source/>Ann Am Thorac Soc
          <year>2019</year>
<volume>16</volume>
<issue>4</issue>
<fpage>509</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1513/AnnalsATS.201807-471RL</pub-id>
<pub-id pub-id-type="pmid">30571922</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rentz</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Skalicky</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Prestifilippo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey</article-title>
<source/>J Patient Rep Outcomes
          <year>2018</year>
<volume>2</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.1186/s41687-018-0055-4</pub-id>
<pub-id pub-id-type="pmid">30294710</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karenfort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Freitag</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pannek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tuxhorn</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Epilepsy surgery outcome in children with focal epilepsy due to tuberous sclerosis complex</article-title>
<source/>Neuropediatrics
          <year>2002</year>
<volume>33</volume>
<issue>5</issue>
<fpage>255</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1055/s-2002-36740</pub-id>
<pub-id pub-id-type="pmid">12536368</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference</article-title>
<source/>Pediatr Neurol
          <year>2013</year>
<volume>49</volume>
<issue>4</issue>
<fpage>255</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.08.002</pub-id>
<pub-id pub-id-type="pmid">24053983</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chopra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Wargon</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Parasivam</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Camphausen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An Australian tuberous sclerosis cohort: are surveillance guidelines being met?</article-title>
<source/>J Paediatr Child Health
          <year>2011</year>
<volume>47</volume>
<issue>10</issue>
<fpage>711</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1754.2011.02038.x</pub-id>
<pub-id pub-id-type="pmid">21449900</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kalhorn</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Moshel</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>WK</given-names>
</name>
</person-group>
<article-title>Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery</article-title>
<source/>Epilepsy Behav
          <year>2009</year>
<volume>16</volume>
<issue>3</issue>
<fpage>454</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2009.08.018</pub-id>
<pub-id pub-id-type="pmid">19767244</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arya</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tenney</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gelfand</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rozhkov</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>DF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions</article-title>
<source/>J Neurosurg Pediatr
          <year>2015</year>
<volume>15</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.3171/2014.10.PEDS14107</pub-id>
<pub-id pub-id-type="pmid">25360852</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>van Huffelen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Algra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Nieuwenhuizen</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Epilepsy surgery in tuberous sclerosis: a systematic review</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<issue>8</issue>
<fpage>1477</fpage>
<lpage>1484</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01117.x</pub-id>
<pub-id pub-id-type="pmid">17484753</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Olasunkanmi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>MacAllister</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Weil</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Uy</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>Quality of life following epilepsy surgery for children with tuberous sclerosis complex</article-title>
<source/>Epilepsy Behav
          <year>2011</year>
<volume>20</volume>
<issue>3</issue>
<fpage>561</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2010.11.003</pub-id>
<pub-id pub-id-type="pmid">21288778</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Morse</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Epilepsy surgery in tuberous sclerosis: a review</article-title>
<source/>Neurosurg Focus
          <year>2012</year>
<volume>32</volume>
<issue>3</issue>
<fpage>E5</fpage>
<pub-id pub-id-type="doi">10.3171/2012.1.FOCUS11330</pub-id>
<pub-id pub-id-type="pmid">22380859</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sparagana</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bebin</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Kuperman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Witt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kohrman</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Flamini</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term use of Everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>6</issue>
<fpage>e0158476</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0158476</pub-id>
<pub-id pub-id-type="pmid">27351628</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Mortality in the Mayo Clinic tuberous sclerosis complex study</article-title>
<source/>Ann N Y Acad Sci
          <year>1991</year>
<volume>615</volume>
<fpage>375</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1991.tb37786.x</pub-id>
<pub-id pub-id-type="pmid">2039164</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vignoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>La Briola</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Volpi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montanari</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Morenghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ghelma</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bulfamante</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cefalo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Canevini</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Do patients with tuberous sclerosis complex have an increased risk for malignancies?</article-title>
<source/>Am J Med Genet A
          <year>2016</year>
<volume>170</volume>
<issue>6</issue>
<fpage>1538</fpage>
<lpage>1544</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.37644</pub-id>
<pub-id pub-id-type="pmid">27061015</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hulbert</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Clinical management of tuberous sclerosis complex over the lifetime of a patient</article-title>
<source/>Pediatric Health Med Ther
          <year>2015</year>
<volume>6</volume>
<fpage>139</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.2147/PHMT.S67342</pub-id>
<pub-id pub-id-type="pmid">29388579</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<mixed-citation publication-type="other">Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav. 2019;91:94–8.</mixed-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<mixed-citation publication-type="other">Dill PE, Datta AN. The mTOR pathway as a therapeutic target for precision medicine. Z Epileptol. 2019;32:292–7.</mixed-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<mixed-citation publication-type="other">Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, French JA, Gil-Nagel A, Hesdorffer DC, Smithson WH, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology. 2017;88(17):1674–80.</mixed-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<mixed-citation publication-type="other">Strzelczyk A, Zschebek G, Bauer S, Baumgartner C, Grond M, Hermsen A, Kieslich M, Krämer G, Kurlemann G, May TW, et al. Predictors of and attitudes toward counseling about SUDEP and other epilepsy risk factors among Austrian, German, and Swiss neurologists and neuropediatricians. Epilepsia. 2016; 57(4):612–20.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>